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Abstract 
A core element in clinical diagnostics is the data interpretation obtained through the 
analysis of patient samples.  To obtain relevant and reliable information, a methodological 
approach of sample preparation, separation, and detection is required.  Traditionally, these 
steps are performed independently and stepwise.  Microchip capillary electrophoresis (MCE) 
can provide rapid and high-resolution separation with the capability to integrate a streamlined 
and complete diagnostic workflow suitable for the point-of-care setting.  Whilst standard 
clinical diagnostics methods normally require hours to days to retrieve specific patient data, 
MCE can reduce the time to minutes, hastening the delivery of treatment options for the 
patients.  This review covers the advances in MCE for disease detection from 2008 to 2017.  
Miniaturised diagnostic approaches that required an electrophoretic separation step prior to 
the detection of the biological samples are reviewed.  In the two main sections, the discussion 
is focused on the technical set-up used to suit MCE for disease detection and on the strategies 
that have been applied to study various diseases.  Throughout these discussions MCE is 
compared to other techniques to create context of the potential and challenges of MCE.  A 
comprehensive table categorised based on the studied disease using MCE is provided. We 
also comment on future challenges that remain to be addressed. 
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Introduction  
A fast, reliable and accurate “sample-in–answer–out” analysis is requested in the 
diagnostic environment.  This is difficult to achieve since most biological samples are 
complex and adequate sample preparation and separation should be performed prior to the 
actual diagnostic interpretation.  The separation step is crucial for obtaining qualitative and 
quantitative clinical information.  In general, the steps in the diagnostic process are 
performed sequentially which can be tedious and resource-intensive.  Thus, the idea to 
integrate a whole analytical laboratory on a small glass chip seemed quite radical when it was 
first proposed by Manz and colleagues in 1990 [1].  This initial “lab on a chip” concept or 
micro total analysis systems (µTAS), also included the birth of microchip electrophoresis 
(MCE).  In MCE, electrophoretic analysis is performed in the short microchannels of the chip 
and the channels can be fabricated for the analytical purpose.  The small channel dimensions 
provide the advantage of applying high electric field strengths that enable fast and high-
resolution separation.  The transition from benchtop analysis to the chip format has found 
wide application in genomics, forensics peptidomics, proteomic, metabolomics, and 
biomarker analysis [2–10] where microchip gel electrophoresis (MGE) and MCE can result 
in performance improvements compared to classical electrophoresis.  The possibility to 
integrate a whole analytical workflow of sample preparation, separation, and detection to the 
chip format further supports point-of-care diagnostics.  This has also significantly influenced 
the emerging field of single-cell analysis [11,12].  An exemplary demonstration is single cell 
western blotting that enables the study of proteins from a single cell with a detection 
sensitivity < 30,000 protein molecules [13]. 
 
Here, we highlight the advancements that amplified the potential of MCE for clinical 
analysis including applications from single cell analysis.  The last review on this topic 
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appeared more than a decade ago [14].  The focus is on targeted separations that were applied 
for the detection of diseases during the period 2008-2017.  The keywords “microchip 
electrophoresis” and “clinical” were searched using the Scopus database.  The review is 
divided into two sections; (1) Background and integration of MCE for disease detection, and 
(2) Clinical applications of MCE.  The first section is for novice readers where we provide a 
brief introduction of MCE and its core units followed by the separation and operation 
principles.  In the second section, we focus on the specific use of MCE for disease 
interrogation.  A comprehensive table based on the diseases studied is presented and this can 
serve as an initial source of information for readers interested in MCE applications. 
 
1. Background and integration of MCE for disease detection  
A MCE setup can be described by the core elements of microfluidic structures, 
electrophoretic separation, and detection unit that build up the miniaturised analytical 
laboratory.  The application of an electric field can be used for sample manipulation (e.g., 
purification, sample concentration) in addition to the separation.  Figure 1 shows a schematic 
of a typical MCE system with a T-shaped microfluidic chip and the required operational 
elements.  The fluidic channels of the chip, sample reservoirs, and buffer reservoirs are 
primed for analysis using appropriate solutions (e.g., background solution, sieving gels, etc.) 
and fluidic controls (e.g., syringe pumps, pipetting).  Once the chip has been prepared and the 
sample injected, a high voltage supply (HV supply) provides the electric field for separation.  
The detector, typically placed at the end of the separation channel, registers the separated 
zones and transmits the data to signal processing unit for conversion into an output format 
(e.g., electropherogram).  This section provides a brief overview on the MCE core elements 
including device fabrication, on-chip sample preparation, electrophoretic separation, and 
target detection.  
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1.1 General approaches to device fabrication and channel design 
1.1.1. Device fabrication 
The microfluidic chips can be fabricated with exquisite control over the fluidic 
structures and these structures can be suited for disease detection.  In general, a microfluidic 
electrophoresis chip consists of a separation channel that is connected to sample and buffer 
reservoirs.  A wide range of materials can be used for chip fabrication and examples of 
common materials are glass, ceramics, and various polymers including poly(methyl 
methacrylate), cyclic olefin copolymer (e.g., TOPAS), polystyrene, and polycarbonate.  The 
biocompatible and low background fluorescence poly(p-xylylene) polymers (e.g., Parylene-
C) was also explored for chip fabrication [15].  Disposable chips made from paper and fabrics 
have further attracted increasing attention which is mainly due to the relatively simple and 
low-cost device fabrication [16].   
 
The fabrication of microfluidic structures is generally performed by microfabrication 
techniques (e.g., photo-lithography, soft-lithography).  Additive manufacturing is 
increasingly explored for microfluidic fabrication, although this fabrication process has not 
yet achieved the precision and resolution of lithography [17].  Similarly, direct printing on 
transparent polyester film with commercial office-type laser printer can be used as fabrication 
alternative.  Although this fabrication method is rapid and cost-efficient, the resolution and 
quality of the printed microchannels are lower compared to photolithographic fabricated 
chips which can lead to shortcomings in separation efficiency and sensitivity.  When filled 
with electrolyte or background solution (BGS), most of the fabrication materials provide an 
electroosmotic flow (EOF).  The EOF can impede on separation and is thus often suppressed.  
EOF suppression is obtained by dynamic and permanent channel coatings and use of 
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hydrogels [18–20].  In addition to EOF suppression, chemical modification of the 
microfluidic channels can also be applied to improve the method performance [21–24].   
 
1.1.2. Channel design 
Widely used chips have a crossed-channel or T-shaped design where the separation 
channel is perpendicularly connected to sample and buffer channels (Figure 1).  Other 
designs for MCE and MGE are also applied.  For instance, the commercial Agilent 
BioanalyzerTM chip contains 16 reservoirs; 12 for samples and 4 for reagents and references.  
The option to fabricate multiple channels and reservoirs supports high-throughput diagnostic 
analysis and structures fitted for purpose.   
 
The main modes of sample injection in MCE are injection by hydrodynamic pressure 
and voltage application.  Hydrodynamic injection was implemented by using an on-chip 
peristaltic pump [28].  Novel injection strategies involved controlled droplet injection using 
inkjet and array technology and these strategies provided advantages of high-throughput and 
precise nano- to picolitre volume injection [29,30].  The channel designs influenced the 
injection mode; electrokinetic injection was the preferred mode due to its simplicity and 
suitability for most channel designs.  In this mode, the amount of injected sample is 
depending on time and applied voltage and biased towards high mobility samples (due to the 
electrokinetic bias [31]).  Hydrodynamic injection was less common because this mode is 
more difficult to implement and often requires an auxiliary (e.g., pump or pipette) for 
injection.  Hydrodynamic injection is performed by difference in fluid levels of sample and 
sample waste reservoir, applying pressure, or vacuum.   
 
The electrokinetic injection modes are pinched, floating, gated, and dynamic 
injections.  In pinched injection, voltage is applied at sample, buffer, and buffer waste 
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reservoir.  The sample waste reservoir is grounded.  This results in injection of the sample 
into the channel junction.  The channel junction is where the sample channel enters the 
separation channel.  The pinched mode enables the injection of a relatively well-defined and 
small analyte plugs.  However, the small plug of injected sample decreases the detection 
sensitivity.  Floating injection is similar to the pinched mode; however, no potential is applied 
between buffer and buffer waste reservoir.  This results in diffusion of the sample into the 
separation channel during the injection and thus increases the sample load.  In gated injection, 
voltage is applied at sample and buffer reservoir and the two waste reservoirs are grounded.  
Next, the voltage at the buffer reservoir is switched off which results in sample injection into 
the separation channel.  This way different amounts of samples can be loaded, and the 
sensitivity is improved.  After injection the voltage at the buffer reservoir is switched on 
again.  The dynamic injection is a variation of the pinched mode, where an additional step is 
introduced.  Electroosmosis is used in this additional step to pump sample into the separation 
channel and thus also increase sample load.   
 
1.2 On-chip sample preparation 
The flexible fabrication of microfluidic chips offers the integration of sample 
preparation including extraction, filtration, isolation/fractionation, and analyte enrichment 
[7].  For instance, a solid-phase extraction unit was incorporated on a MCE device [32].  A 
polymer solution was filled in a channel of the microfluidic chip and in-situ 
photopolymerisation was applied to create the monolithic absorbance material for on-chip 
solid-phase extraction. The extraction unit provided a model analyte enrichment of a factor 
up to 80.  Suitable analyte enrichment/stacking approaches for the chip setup are similar to 
the approaches established in capillary electrophoresis (CE); field-
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
8 
 
amplification/enhancement, transient isotachophoresis, sweeping, and micelle to solvent 
stacking [33–38].   
 
Nucleic acids were enriched by an on-chip amplification strategy using polymerase 
chain reaction (PCR) and digital loop-mediated isothermal amplification analysis [39].  A 
single chip quantitative multiplexed PCR assay for phiX174 bacteriophage sequences and E. 
Coli was demonstrated and enabled target amplification from as little as 50 DNA copies in 
the sample [40].  The assay of PCR and electrophoretic separation was completed in 45 min.  
A two-chip system was demonstrated for optimised real time PCR followed by MGE 
separation of the amplicons [41].  The first chip was used for microfluidic real time PCR 
while the second chip was for separation of the amplicons.  A heat sink and optimised PCR 
protocol was applied to shorten the DNA amplification process by factor 3 or approx. 30 min 
compared to typical 90 min.  The heat sink enabled fast heating rates and isolated cooling 
within the small space of the microchip.  Further, the time for thermal equilibration was 
removed which further helped to speed-up the amplification process without compromise in 
the amplification of the model gene β2 microglobulin. 
 
1.3 Electrophoretic separation 
The electrophoretic separation of the sample is achieved by the application of an 
electric field along the separation channel (Figure 1).  The electric field results in 
electrophoretic migration and flow of liquid called as EOF.  The capillary electrophoretic 
separation modes are zone electrophoresis [42], electrokinetic chromatography [43,44], and 
gel electrophoresis [45].  In MCE, the modes of zone electrophoresis, gel electrophoresis and 
dielectrophoresis (DEP) are most commonly applied.  DEP is used for isolation of particles 
and cells under the influence of an non-uniform electric fields [46].  For instance, polystyrene 
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microbeads and PC-3 human prostate cancer cells could be separated with high confidence 
using self-assembled ionic liquid electrodes [47].  The capability of DEP to separate particles 
can also be used for on-chip extraction of plasma from whole blood [48].  In zone 
electrophoresis, charged analytes migrate through a liquid BGS and are separated according 
to their apparent electrophoretic mobility where the analytes are detected with descending 
mobility.  Zone electrophoresis has found wide application including the separation of small 
molecules such as drugs and metabolites.  
 
In gel electrophoresis, the electric field is applied along a sieving matrix.  The charged 
analytes migrate through the matrix where larger molecules are more retained than smaller 
molecules. The sieving matrix is made from porous gels and the gel mesh size affects the 
analyte resolution.  For instance, an increase in the concentration of highly cross-linked gels 
generally improves resolution.  However, high sieving matrix concentrations also increase the 
viscosity and gels with high viscosity can be difficult to load into the microfluidic structures.  
Common gels are made from polyacrylamide, cellulose, agarose, and starch.  Gel 
electrophoresis is used for size-based separation of large biomolecules including proteins, 
DNA, and RNA.  Amplification of DNA and RNA by PCR is often applied to concentrate the 
analyte prior to the separation.  The transition from slab gel electrophoresis to the microchip 
format offers improvements in analysis time and base pair (bp) resolution [49].  For instance, 
MGE typically provides analysis times of 1-10 min and can achieve single base pair 
resolution.  
 
1.4 Target detection 
After the separation in the microfluidic channel, sample detection is performed.  The 
detection was performed by the modes of laser-induced fluorescence (LIF), 
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chemiluminescence, electrochemical, and absorbance measurement.  LIF was the most 
frequent detection mode accounting for ~3/4 of the reviewed articles.  Reasons for the 
popularity of LIF might be the high detection sensitivity and wide availability of this 
detection mode.  Further, LIF is the predominant detection mode for nucleic acid analysis.  
  
In LIF, the fluorescent analyte is excited with a laser and the emitted light when the 
analyte returns to the ground state provides the detection signal.  Autofluorescence is 
relatively uncommon and thus fluorescent derivatisation is generally applied to suit the 
analyte for detection.  The derivatisation can be performed before injection and in-channel 
[50].  Fluorescence detection can also be extended to simultaneously detect multiple analytes.  
For instance, a two laser setup was used for parallel excitation in the visible-light and near-
infrared wavelength range of three labelled metabolites [51].  Light and laser emitting diodes 
have attracted interest as low-cost and portable alternatives to more expensive lasers and 
were often integrated into commercial chip electrophoresis instruments.  Although LIF is a 
highly sensitive detection mode, the small injected sample volumes and narrow structures of 
the microfluidic chip diminish the detection sensitivity.  A fluorescence signal amplification 
strategy for highly sensitive detection of pM-levels of interferon-gamma by chip 
electrophoresis-LIF was developed [52].  Hereby, the signal amplification was achieved by a 
repeated cycling of cleavage and accumulation of the fluorescence reporter. This cycling was 
dependent on target binding to the hairpin aptamer probe.    
 
In chemiluminescence detection, the analyte is excited by the adsorption of energy 
released from a chemical reaction.  The emitted light when the excited analyte returns to its 
ground state is measured.  This detection mode is highly sensitive and can further be 
enhanced by using reaction modifiers to achieve fM to aM detection limits.  An example of a 
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common chemiluminescence reaction is the oxidation of luminol.  In this reaction, luminol is 
oxidised in alkaline conditions using hydrogen peroxide as an oxidiser and horseradish 
peroxidase (HRP) as the catalyst.  The signal can further be enhanced when other modifiers 
such as p-iodophenol are present in the luminol reaction.  
 
In electrochemical detection, the modes of amperometric and capacitively coupled 
contactless conductivity are generally applied.  In amperometric detection, the current change 
is measured when the analyte band passes the detector.  Capacitively coupled contactless 
conductivity detection is similar and changes in conductivity are registered, however, the 
detection unit is not in contact with the separation solution.  The detection probe is placed 
outside the microfluidic channel.  The relatively low cost and compact design of 
electrochemical detectors were early recognised for its potential in portable and point-of-care 
applications [53]. 
 
2. Clinical application of MCE 
Tables 1 summarises the reviewed papers based on the type of disease.  The table 
includes 33 contributions on cancer, 9 on immune disorders, 9 on neurological diseases, 8 on 
genetic disorders, 8 on cardiovascular diseases, 7 on infectious diseases and pathogens, 7 on 
organ diseases and dysfunctions, 5 on diabetes and pancreatic dysfunction, and 4 on 
reproductive disorders. 
 
2.1 Cancer 
MCE was applied to investigate lung, gastric, blood, colorectal, prostate, oral, liver, 
gynecologic (i.e., ovarian and cervical), and bladder cancers.  General cancer biomarkers that 
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are typically found in the progression of this disease were also analysed.  Anticancer drug 
screening was further investigated, for instance by the use of DEP cellular microarrays [54]. 
 
The MCE strategies to investigate cancer were by the quantification of proteins, 
peptides, and small molecules, and mutation analysis of DNA and RNA from tissue samples 
and biological fluids.  An exemplary workflow for quantification of proteins, peptides, and 
small molecules consisted of sample preparation (e.g., target isolation, concentration, 
derivatisation) followed by electrophoretic separation and detection.  Chip-based 
immunoassays were important for antigen detection.  For DNA and RNA, an exemplary 
workflow included extraction of the nucleic acid, target amplification by PCR, and size-based 
gel electrophoretic separation followed by fluorescence detection.  The extraction of DNA 
from cells was by cell lysis including the addition of proteases and RNases to break down 
proteins and RNAs, and centrifugation to separate the solid debris from the supernatant.  The 
supernatant contained the DNA for further purification and isolation by ethanol precipitation, 
phenol-chloroform extraction, or solid-phase extraction.   
 
Widely used RNA isolation techniques included liquid-liquid extraction (e.g., acid 
guanidinium thiocyanate-phenol-chloroform extraction [55]) and solid-phase extraction 
procedures.  However, the isolation of RNA is more difficult than for DNA since RNA is 
prone to degradation.  For instance, a study on the effects of RNA storage time and 
conditions showed that RNA could be stored up to 30 months at -80 ºC and short time storage 
of up to 4 h on ice [56].  However, degradation occurred at room temperature and in saline 
solution (i.e., in 0.9 M NaCl).  The degradation was determined using the RNA integrity 
value.  This value represents a semi-quantitative evaluation of RNA quality.  The value 
ranges from 1 to 10 where 1 is completely degraded and 10 is unmodified RNA.  The RNA 
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integrity value is calculated based on peak shape and height obtained by MGE [57].  The 
value was further applied to the evaluation of RNA quality in renal carcinoma tissue samples 
[58].  The tissue samples were stored for <6 to 30 months at -80°C.  In addition, tissue 
samples were also stored in similar conditions as typically found during tissue transportation 
(e.g., at room temperature, on ice, or saline solution).  Storage at -80°C for up to 30 months 
and 4 h on ice provided integrity values of >7 or intact RNA, while degradation was detected 
when the RNA was stored in saline solution and at room temperature.  
 
2.1.1 General cancer biomarkers 
The general cancer biomarkers that are found in various types of cancer included 
telomerase activity, carcinoembryonic antigen, and DNA mutations in p53 oncogenes. 
 
Telomerase activity has been associated with carcinogenesis where the telomerase 
activity inhibits the telomere shortening during replication [59].  The telomeric repeat 
amplification protocol based on genetic analysis is widely used to assess the telomerase 
activity.  This method was transferred to the chip format [60,61].  Although the chip format 
provided fast amplicon separation (e.g, 2 min) and sensitive detection (e.g., single cells 
analysis after 20 PCR cycles), multiple steps of sample preparation have to be performed 
manually (i.e., cell lysis, DNA extraction, and PCR amplification).   
Carcinoembryonic antigen [62,63] and thymidine kinase 1 [64] were determined 
using a non-competitive immunoassay and aptamer-based microchip electrophoresis assay 
with LIF detection.  Carcinoembryonic antigen is a protein biomarker used in the diagnosis of 
colorectal, pancreatic, gastric, ovarian, and cervical carcinomas.  In the non-competitive 
immunoassay, the sample was off-line incubated with a primary antibody for 45 min before a 
second step of incubation with a secondary fluorescein isothiocyanate (FITC)-labelled 
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antibody.  Electrophoretic separation was required to separate the free FITC-labelled 
secondary antibody, non-target complex of primary-secondary antibody, and target complex 
of biomarker sandwiched between primary and secondary antibody.  The addition of 30 mM 
sodium dodecyl sulfate (SDS) to the BGS helped to suppress biomolecule adsorption on the 
channel wall.  This immunoassay afforded a target detection in 4 min with limits of detection 
of 45.7 pg mL-1.  The analysed healthy and patient serums showed carcinoembryonic antigen 
concentration of 2.9-5.1 ng mL-1 and 158.3-270.1 ng mL-1, respectively.  For comparison, in 
common fluorescence-based sandwich immunoassays, the antigen is sandwiched between 
capture and detection antibody. The capture antibody (e.g., anti-carcinoembryonic antigen 
antibody) is immobilised on a substrate.  Instead of using an electrophoretic separation of 
free/unbound label from the antibody-antigen sandwich complex, multiple washing steps are 
required.  Typically, this assay format requires 60 min of the result and the detection limits 
are < 5 ng mL-1 [65].  
 
Single-base mutations in the p53 gene have a higher prevalence for the development 
of cancer and are the most commonly mutated gene in human cancers [66].  The p53 gene 
composes more than 20000 bp, 11 exons, and 10 introns.  Gene mutations in p53 were 
analysed by single strand conformational polymorphism (SSCP) and heteroduplex analysis 
(HA) in combination with MGE-LIF [67].  In the processes of SSCP and HA, different DNA 
conformations of mutated and unmutated DNA are obtained which results in electrophoretic 
mobility differences that can be separated.  Five single-base substitutions in p53 exons 5–9 in 
106 tissue samples were analysed in the blinded study and the samples were correctly 
identified with 98% sensitivity and 100% specificity.  The method could analyse as low as 
15% mutant tissue from a mixed tissue biopsy sample that comprised of cancerous (mutant) 
and healthy tissue material. 
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2.1.2 Lung cancer 
Mutations in the EGFR gene [68,69] and determination of neuron-specific enolase 
[70] were used to study lung cancer.  
 
Multiplexed ligation-dependent probe amplification [68] and fragment length assay 
[69] followed MGE-LIF were applied to detect EGFR mutations in exons 19 and 21 of 
patients with non-small cell lung cancer.  For the multiplexed ligation-dependent probe 
amplification, the tissue extracted DNA was subjected to amplification and the products were 
loaded into a separation gel containing 7 M urea for DNA denaturation.  The modified 
heating element of the commercial instrument enabled to perform separations at 65 °C 
instead of 50 °C.  The sieving matrix and elevated temperature provided fragment resolution 
of as low as 2 bp which was sufficient to resolve the small difference between the wild-type 
(i.e., 320 bp) and mutant fragment (i.e., 305 bp) in less than 90 s of separation time with as 
little as 40 fluorescently labelled DNA fragments for injection. 
 
An off-line competitive immunoassay for neuron-specific enolase based on 
chemiluminescence resonance energy transfer was demonstrated [70].  The competition was 
between HRP-labelled antigen and the unlabelled antigen in the sample.  An increase in 
sample antigen concentration resulted in a decrease in signal intensity due to the competition 
with the HRP-labelled antigen.  The chemiluminescence was triggered by HRP and luminol 
as the donors and fluorescein isothiocyanate as an acceptor in the presence of oxidiser 
solution containing hydrogen peroxide and signal enhancer p-iodophenol.  The oxidiser 
solution was delivered from an additional channel in front of the detection point.  This 
methodology afforded 4.5 pM detection limits and was evaluated on serum samples from 
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healthy subjects and lung cancer patients where >10-times higher antigen concentrations 
were found in the patient samples (>96 pM).  The successful integration of the immunoassay 
with chemiluminescence detection required a careful optimisation of the separation 
conditions.  Relatively small changes in solution pH, ionic strength, and temperature affected 
the chemiluminescence signal.  This can result in a challenging situation for MCE devices 
that aim for portability.   
 
2.1.3 Blood cancer 
The types of blood cancers that were studied included canine T-cell lymphoma, 
leukaemia and lymphoblastic leukaemia, follicular lymphoma, and myeloproliferative 
neoplasms.  Canine T-cell lymphoma was studied by detection of the V and J variable regions 
in the T-cell receptor γ gene in an approach of target amplification followed by fast amplicon 
separation in 10 s using an electric field gradient [71].  
 
Leukaemia and lymphoblastic leukaemia were investigated using variable number of 
tandem repeats (VNTRs) [72].  Hematopoietic stem cell transplantation is used in the 
treatment of leukaemia.  To evaluate the outcome of the transplantation, the sequencing of the 
donor DNA in the receiver’s blood and cord blood was analysed to assess the degree of 
chimerism.  Genomic DNA of the donor and receivers blood sample was amplified and a 
standard curve from mixed patient-donor VNTRs by serial dilution was created.  As low as 
6.3% donor DNA could be determined in the receiver’s blood. 
 
Follicular lymphomas were investigated by identification of Bcl-2/IgH fusion [73] 
and B-cell clonality [74].  A specific translocation between the Bcl-2 and IgH gene is found 
in more than 85% of patients with nodal follicular lymphoma [75].  The size of the fusion 
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gene formed by the translocation is different from clone to clone.  The fusion was detected by 
MGE-LIF of the real-time PCR amplified products [73].  The method could differentiate 
fusion genes with differences less than 9 bp or 5%.  The B-cell clonality was analysed by 
amplification of three subregions of the Ig heavy chain gene and rearrangements in the Ig κ 
chain gene prior to the size-based separation and LIF detection using a simplified BIOMED-2 
protocol [74].  The amplicons were subjected to heteroduplex analysis.  A sensitivity of 10% 
target DNA in non-target DNA was achieved. The method was compared to the same 
protocol using CE, where CE provided better sensitivity and could detect as low as 1% target 
DNA in non-target DNA.  
 
Myeloproliferative neoplasms have different subtypes where polycythemia vera, 
essential thrombocythemia, and primary myelofibrosis are the most common.  The 
identification of the subtype is important for treatment; however, the correct identification is 
challenging.  High resolution melting analysis and PCR-MGE-LIF were used for genotyping 
of 99 myeloproliferative neoplasms samples [76].  The approach analysed for mutations in 
Janus kinase 2 and calreticulin genes. From the 99 samples, 60 showed a mutation in Janus 
kinase 2.   From the 39 samples without the Janus kinase 2 mutation, 14 had a mutation in the 
calreticulin gene.  The combined analysis of both genes improved the diagnostic accuracy.  
 
2.1.4 Colorectal cancer 
Colorectal cancer was investigated by low-abundance KRAS mutations detection 
[77], microsatellite instability [78], and glycomic serum analysis [79].  
 
The treatment with monoclonal antibodies cetuximab and panitumumab can help to 
improve the median overall survival and 5-year survival rates, however, only if the patients 
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have a non-mutated form of the KRAS gene [80].  A sensitive method for the detection of 
mutations in the KRAS gene of colorectal cancer patients involved restriction fragment 
length polymorphism and stacking MGE [77].  Figure 2 shows the methodological approach.  
To detect the point mutations in codon 12, a 107-bp fragment of KRAS was amplified from 
DNA templates extracted from cancer cells or tissue samples and amplified using 
mismatched primer PCR.  The mismatched forward sense primer introduced a base to the 
unmutated or wild-type fragment for specific digestion with Mva I restriction endonuclease.  
The digestion resulted in a 77 and 30 bp fragments that gave rise to two peaks in the 
electropherogram.  The mutant remained undigested and a single peak was detected.  The 
heterozygous contained wild-type and mutant DNA fragments which resulted in a combined 
electropherogram of the two. This combination of restriction fragment length polymorphism, 
stacking and fluorescence detection could detect as low as 0.01% mutant DNA mixed with 
wild-type DNA.  For comparison, standard SDS-PAGE was three orders of magnitude less 
sensitive and could detect as low 10% mutant DNA.  
 
The characterisation of N-glycans in human serum by MALDI-MS and MGE-LIF was 
used to distinguish colorectal cancer patients from healthy subjects [79].  After digestion, 
isolation, and derivatisation of the N-glycans from 42 patients and 20 control serum samples, 
the analytes were electrophoretically separated and the electropherograms were correlated 
with the glycan mass spectrum information.  The electropherogram revealed the presence of 
isomeric glycan species as two peaks which were detected as a single peak with an identical 
m/z ratio in the mass spectrum.  An example of a patient’s N-glycan profile is shown in the 
electropherogram in Figure 3.  Changes in the position of fucose and fucosyl isomeric 
species were found in the cancerous samples.  The patient samples showed elevated serum 
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levels of fucosylated tri- and tetra-antennary glycans and this difference in concentration and 
profile could be used for diagnosis.  
 
2.1.5 Prostate cancer 
Prostate cancer was studied by analysing the circulating cell-free DNA in patients 
with hormone-refractory prostate cancer [81].  After extraction of the DNA from plasma, 
quantitative PCR and MGE-LIF were used to determine the concentrations of cell-free DNA 
during chemotherapy.  The concentration of cell-free DNA increased on average from 13.3 
ng mL-1 to 46.8 ng mL-1 from before treatment to after the first cycle of chemotherapy, 
respectively.  Cell-free DNA prior treatment was mainly composed of small DNA fragments 
in the range of 160–200 bp while larger fragments of 200-10.4 kbp were found after 
treatment.  This was attributed to necrotic cell lysis and thereby the release of large fragments 
into the bloodstream.  
 
2.1.6 Oral cancer 
Skin cancer was investigated from patients with oral squamous cell carcinoma using 
DNA methylation analysis and MGE-LIF [82].  The non-invasive strategy applied 
methylation-specific PCR to the extracted DNA (13 targeted genes) from oral rinse of 34 
patients and 24 healthy subjects.  Significantly elevated levels of DNA methylation was 
found in eight genes (i.e., e-cadherin (ECAD), transmembrane protein with epidermal growth 
factor-like and 2 follistatin-like domains 2 (TMEFF2), retinoic acid receptor beta (RARβ), O-
6 methyl-guanine DNA methyltransferase (MGMT), fragile histidine triad gene, WNT 
inhibitory factor 1, cyclin-dependent kinase inhibitor 2A, and death-associated protein kinase 
1).  Using a selected panel of four hyper-methylated genes (i.e., ECAD, TMEFF2, RARβ, 
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and MGMT), oral squamous cell carcinoma could be accurately diagnosed with 100% 
sensitivity and 87.5% specificity. 
 
2.1.7 Liver cancer 
Liver cancer was studied using immunoassay MCE for the determination of α-
fetoprotein, carcinoembryonic antigen, prothrombin, and des-γ-carboxy prothrombin.  
Amperometric detection was integrated into an enzymatic immunoassay-based MCE device 
for sensitive detection of α-fetoprotein and carcinoembryonic antigen in patients with liver 
and colonic cancers and healthy subjects [83].  Figure 4 shows the immunoassay approach 
integrated on the T-shaped microchip.  The sample was placed in reservoir 2 and 
electrokinetic injection introduced the off-line labelled analytes into the separation channel 
(i.e., a channel connecting 1 and 4).  An additional channel and reservoir (5) were fabricated 
to the T-shaped chip in order to deliver the substrate for enzymatic reaction (i.e., 2-
aminophenol).  A voltage of 1.0 kV was applied to this channel to introduce the substrate into 
the separation channel.  The separation buffer contained hydrogen peroxide to complete the 
enzymatic assay together with HRP and the substrate to produce the electroactive product 
(i.e., 3-aminophenoxazine) for amperometric detection.  Amperometric detection can be 
label-free and has a comparable sensitivity to fluorescence detection.  However, to avoid 
detection interferences occurring from the applied electric field, the amperometric detector 
had to be shielded or decoupled from the electrophoretic separation.  
 
Sensitive determination of α-fetoprotein is important because it could be used to 
predict the recurrence of cancer after curative treatment and for detecting small tumours at an 
early stage of the cancer progression.  Highly sensitive immunoassays for α-fetoprotein were 
achieved by transient isotachophoresis and fluorescence detection [84] and lectin-affinity 
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chip electrophoresis [85].  The lectin-affinity electrophoresis was a liquid-phase binding 
assay that achieved a detection sensitivity of 0.3 ng mL-1 analyte in serum.  The transient 
isotachophoresis approach achieved 5 pM sensitivities and the stacking was further beneficial 
to significantly sharpen the analyte band.  Both detection sensitivities were much lower than 
the clinical cut-off concentration of 280 pM.  The stacking immunoassay was then extended 
for the determination of lens culinaris agglutinin-reactive α-fetoprotein, total α-fetoprotein, 
and des-γ-carboxy prothrombin [86].  In a similar study, the diagnostic precision of liver 
cancer (i.e., hepatocellular carcinoma) could be improved by considering a panel of three 
biomarkers (i.e., α-fetoprotein, fucosylated fraction of α-fetoprotein, and prothrombin 
induced by vitamin K absence-II ) that enabled the detection of 81.8% of early-stage 
hepatocellular carcinoma, 86.7% of small-sized tumour, and 91.7% of single tumour [87]. 
 
2.1.8 Gynecologic cancers 
Ovarian and cervical cancers were investigated by the profiling of N-glycans of 
patient serum samples [88], identification of human papillomavirus [89,90], and 
determination of β-subunit of human chorionic gonadotropin [91].  The serum N-glycan from 
patients diagnosed with late-stage recurrent ovarian cancer were obtained after denaturation, 
disulfide bond reduction and enzymatic release of the glycans with peptide-N-glycosidase F.  
The glycans were then isolated by solid-phase extraction on activated carbon micro spin 
columns followed fluorescence labelling with APTS (8-aminopyrene-1,3,6-trisulfonic acid).  
The labelled glycans were injected and the peak area of the 50-60 most intense peaks and 
their migration time was used for profiling and statistical evaluation (i.e., ANOVA and 
principal component analysis).  The electropherogram profile of control, patients before and 
after drug treatment could clearly be differentiated. The assay was deemed as a highly 
accurate test according to the receiver operating characteristics (ROC) test >0.90. 
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Some types of human papillomavirus (HPV) are linked to the development of cervical 
cancer. A method for HPV identification applied restriction fragment length polymorphism 
followed by gel electrophoretic separation with LED-induced fluorescence detection [89].  
The extracted and purified DNA from tissue samples were subjected to PCR followed by the 
digestion with four different endonucleases.  The endonucleases cleaved the DNA amplicons 
on virus type-specific sites and the separation of these fragments resulted in characteristic 
electrophoretic profiles.  The method provided detection limits of as low as 2 x 102 DNA 
copies.  A similar assay was applied for virus types HPV16 E6/E7 mRNA detection using 
reverse transcription-polymerase chain reaction for target amplification [90]. 
 
The determination of β-subunit of the hormone human chorionic gonadotropin can be 
used as a tumour marker for choriocarcinoma.  A non-competitive immunoassay with 
chemiluminescence detection for the β-subunit was demonstrated [91].  This assay was 
evaluated on serum samples from healthy subjects and ovarian cancer patients and analyte 
concentrations of 9.5-15.7 mIU mL-1 and 160.9-210.4 mIU mL-1 were found in healthy and 
cancer samples, respectively. 
 
2.1.9 Bladder cancer 
Bladder cancer was studied by multiplexed microfluidic immunoassay using DEP 
[92,93] and MGE-LIF [94].  The biomarker panel included galectin-1, lactate dehydrogenase 
B, and bladder cancer-specific genes FGFR3, TERT, HRAS, ALX4, RALL3, MT1A, and 
RUNX3.  Cell lysate from bladder cancer cell lines RT4 and T24 were analysed for protein 
expression of galectin-1 and lactate dehydrogenase B by DEP immunoassay with antibody-
functionalised nanoprobes [92].  The cell lysate was incubated with the nanoprobes.  DEP 
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was applied to focus, guide, and trap the nanoprobes on the microfluidic device using an 
indium tin oxide electrode.  The use of indium tin oxide was beneficial for fluorescence 
imaging because it reduced the background noise level and improved the fluorescence 
response.   
 
Size-based filtration was applied as a fast approach for the isolation of bladder cancer 
cells from human urine [94].  The cells were isolated using a polycarbonate membrane with 8 
µm pores size.  Three bladder cancer cell lines (i.e., T24, 5637, and J82) and human 
umbilical vein endothelial cells were spiked into the artificial urine sample.  The filter 
membrane with cells was washed and the cells eluted with dichloromethane, washed, 
centrifuged, and the cell pellet was dried before the genomic DNA extraction.  Methylation-
specific PCR amplified the mutated and bladder cancer-specific genes FGFR3, TERT and 
HRAS and methylated genes ALX4, RALL3, MT1A, and RUNX3.  Identification of the 
amplicons was by MGE-LIF in less than 2 min.  
 
2.2 Immune disorders  
Immune disorders including inflammatory diseases [95,96], allergic reactions and 
hypersensitivities [97–101], arthritis and gout [102,103] were investigated.   
 
2.2.1 Inflammation 
For inflammatory diseases, the general inflammation markers such as cytokines and 
C-reactive protein were determined by competitive and non-competitive immunoassays.  
These immunoassays used the specific interaction of antibodies to capture the antigens.  The 
incubation of the sample with antibody was performed off-line or on-chip prior to the 
electrophoretic separation of the antigen-antibody complex from the free label.  In the 
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competitive format, the target competes for antibody binding with a labelled non-target.  The 
decrease in labelled non-target is measured and inversely proportional to the target 
concentration.  In the non-competitive format, the target is incubated with antibody and label, 
and the target concentration was proportional to the signal intensity of the target-antibody-
label complex.  
 
The chronic inflammation marker C-reactive protein was analysed using an off-line 
immunoassay followed by MCE-LIF [95] and immunoprecipitation-MGE-LIF [96].  The 
immunoassay was performed in a standard microtiter plate and with functionalised polymer 
beads.  In this format, termed as cleavable tag immunoassay, a three-step incubation 
procedure was performed.  First, microbeads functionalised with capture antibody were 
incubated with the sample.  Second, the beads were incubated with the fluorescently-tagged 
detection antibody.  Third, a cleavage solution (i.e., tris(2-carboxyethyl)-phosphine) was 
incubated to cleave the antigen from the capture antibody.  The cleavage solution reduced the 
disulfide bond of the fluorescence tag and released the tag for subsequent detection.  The 
fluorescence tags were then electrophoretically separated and each tag was specific to a 
single analyte.  An advantage of this assay was that the cleaved label could be detected as a 
free molecule rather than antibody-antigen-label.  Further, baseline separation of the different 
free labels was not required since each label provided a characteristic signal (barcode 
strategy).  Although the separation was fast (2 min), the incubation time for the immunoassay 
and the cleavage step required multiple hours.  
 
The C-reactive protein from serum of sepsis patients was isolated by 
immunoprecipitation following quantification by MGE-LIF [96].  To suit the samples for 
immunoprecipitation, interfering non-target proteins (e.g., immunoglobulin G and human 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
25 
 
serum albumin) were removed using spin column cartridges followed by fluorescence 
labelling of the analytes in the eluate.  The immunoprecipitation was performed from 10 µL 
eluate using antibody-functionalised magnetic beads.  The target protein was eluted from the 
beads and subjected to gel electrophoretic separation.  This approach was well suited for 
small sample volumes.  As little as 50 µL of patient serum was sufficient as starting material 
and the assay provided an analyte sensitivity of 126 pg µL-1.  
 
2.2.2 Allergic reactions and hypersensitivities 
To investigate allergic reactions, a non-competitive on-chip immunoassay was applied 
for the determination of inflammatory cytokines from skin biopsies in patients with atopic 
dermatitis to nickel [97,98] and in the cerebral spinal fluid of preterm babies with traumatic 
head injury [99].  The microfluidic chips combined affinity-based isolation of cytokines, 
fluorescence-labelling, and separation of labelled cytokines.  The determined cytokines were 
interferon gamma, interleukin-6, and tumour necrosis factor alpha.  The on-chip 
immunoassays were by functionalisation of glass fibre disks with the capture antibodies (i.e., 
chimeric receptors for the targets).  Microdissected skin samples were extracted prior to the 
preconcentration and purification using the immunoaffinity disks.  Figure 5 (i) shows the 
methodological approach for the immunoaffinity disk assay.  The sample was brought in 
contact with antibodies immobilised on the fibre disk (“1. Inject”) for 5 min followed by a 
wash step to remove the sample matrix (“2. Wash”).  A syringe pump delivered a flow of 
labelling solution to fluorescently label the captured cytokines (“3. Label”) before their 
elution with an acidic elution buffer (“4. Elute”).  A voltage was applied to guide the labelled 
analytes into the separation channel following separation of the three targets in less than 3 
min.  The whole workflow was completed in less than 15 min and the assay provided sub-pg 
per microliter detection sensitivity.  Figure 5 (ii) shows the electropherograms from the 
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analysis of (A) normal subject and patients with (B) mild inflammatory lesions and (C) 
severe recurrent inflammatory lesions.  This example of the on-chip integration of an 
immunoassay and electrophoretic separation was suitable for very small sample volumes of 
as low as 0.5 µL and provided a faster and more sensitive diagnostic alternative to commonly 
used enzyme-linked immunosorbent assay (ELISA).  
 
Warfarin hypersensitivity was analysed by genotyping using single nucleotide 
polymorphisms for genes cytochrome P450 variant 2C9 and VKORC1 [100,101].  In these 
approaches, PCR and electrophoretic separation were both integrated on-chip.  In [100], a 
tetraprimer amplification refractory mutation system was selected, in which the Taq 
polymerase only amplified when the primer exactly matched the DNA.  This selective 
amplification process was applied to identify the presence or absence of the target allele.  35 
patients with and without warfarin sensitivity were analysed using as little as 270 nL sample 
for PCR.  The total analysis time of this combined microfluidic approach was 90 min for 12 
samples.  
 
In [101], the integrated and automated microchip system performed sample 
preparation, PCR amplification, and amplicon separation.  A photograph of the integrated 
microchip system is shown in Figure 6A.  Sample preparation and PCR amplification were 
performed with the disposable elongated chips (“Plastic DNA extraction and amplification 
chip”).  These chips were connected to the gel electrophoresis chip using a PDMS block.  The 
entire analytical workflow was completed in 2 h and required as little as 0.5 µL sample.  The 
method was evaluated on whole blood, dried blood spots and buccal swabs.  An exemplary 
genotyping analysis is shown in Figure 6B, where the target DNA fragments corresponded 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
27 
 
with the typical wild type fragment size.  This strategy was suggested for personalised 
warfarin dosing in clinical practice to mitigate side effects from drug overdosing.   
 
2.2.3 Arthritis and gout 
Arthritis and gout were investigated by on-chip electrophoretic quantification with 
electrochemical detection of lactate in synovial fluid of arthritis patients [102] and uric acid 
in urine of gout patients [103].  Synovial fluid is found in synovial joints (e.g., hip joint) 
where the fluid reduces the friction in the joint during movement.  Increased concentrations 
of lactate are found in patients suffering from arthritis.  The concentration of lactate in 
synovial fluid was determined by MCE with contactless conductivity detection.  Synovial 
fluid samples from 10 volunteers were analysed and lactate concentration in the range of 0.54 
to 5.37 mM was detected.  The method was sensitive to detect as low as 6.5 µM and was 
rapid with 40 s separation time.  
 
2.3 Neurological diseases  
Neurological diseases including multiple sclerosis [104], epilepsy [105,106], bipolar 
disorder [107,108], and Alzheimer’s disease [109–112] were investigated 
 
2.3.1 Multiple sclerosis 
A protein profiling strategy to differentiate patients with multiple sclerosis and 
healthy subjects using MGE-LIF was established [104].  Cerebrospinal fluid and serum 
samples were analysed to create an electrophoretic protein profile that included common 
proteins such as albumins and α-, β-, and γ-globulins.  Characteristic protein profiles were 
found that enabled the differentiation of patient and healthy samples.   
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2.3.2 Epilepsy  
Phenobarbital is administered in the treatment of epilepsy patients.  Competitive 
immunoassays for phenobarbital in serum samples of epileptic patients were performed 
[105,106].  The serum samples were subjected to liquid-liquid extraction, evaporation and 
reconstitution in a buffer prior to the immunoassay procedure.  The extracted drug competed 
with a fluorescently-labelled phenobarbital for binding to the antibody.  The signal of the 
labelled drug was inversely proportional to the analyte concentration in serum.  The analysed 
patient samples showed concentrations in the range of 66.4–155.6 µM which were all within 
the therapeutic range (i.e., 43-172 µM).   
 
2.3.3 Bipolar disorders 
Lithium is used as a mood-stabiliser in the treatment of bipolar disorders.  Due to the 
narrow therapeutic range of this drug in the blood (i.e., 0.4-1.2 mmol L-1), a close monitoring 
of the blood lithium concentration is recommended.  Lithium was determined using MCE 
with conductivity detection from whole blood [107], and urine samples [108].   
 
In [107], the point-of-care device for whole blood analysis consisted of a disposable 
microfluidic chip that was sealed and prefilled with buffer solution.  To introduce the 
positively-charged ions from a droplet of blood, a voltage with a positive sign at sample inlet 
reservoir was applied to introduce the ions into the orthogonal separation channel.  The 
negatively-charged blood cells and anions remained in the sample reservoir.  Destacking or 
band broadening of the injected analytes occurred due to the high sample conductivity.  To 
enable quantification and to account for the effect of destacking, the sample conductivity was 
on-chip measured before sample injection, and an internal standard was further added to the 
sample.  After injection, lithium was separated from sodium and other small inorganic ions 
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and electrochemically detected.  The development of a disposable chip required to address 
some technical challenges.  For instance, buffer evaporation and temperature fluctuations had 
to be considered for achieving stable device performance.  The time for sample-in-answer-out 
was 3.5 min including analyte separation in 30 s.  
 
2.3.4 Alzheimer’s disease 
Alzheimer’s disease is a neurodegenerative disease that is associated with elevated 
levels of phosphorylated tau protein and β-amyloids, and the toxic protein aggregation in the 
brain.  An on-chip hyphenation of isoelectric focusing and zone electrophoresis strategy was 
applied to study protein aggregation [109].  The β-amyloid peptides were investigated by 
immunocapture of the peptides from cerebrospinal fluids and subsequent electrophoretic 
enrichment and separation prior to the fluorescence [110] and mass spectrometric detection 
[111]. The effect of β-amyloid Aβ25–35 treatment on the concentration of essential inorganic 
ions (i.e., Na+, K+, Ca2+, and Mg2+) in neuron-like PC-12 cells was studied with single-cell 
resolution [112].  In order to achieve single-cell injection, the cell solution was introduced to 
the microfluidic channel and a short voltage pulse (i.e., 1s at 800 V) was applied to introduce 
a single cell from sample to the perpendicular separation channel.  Immediately after this 
pulse, a high electric field was applied for single cell lysis following separation and 
fluorescence detection of the inorganic ions.  
 
A device for the isolation of β-amyloid peptides and their mass spectrometric peptide 
identification was demonstrated [111].  Figure 7(A) shows the methodological workflow.  
Before the sample introduction, the bulk β-amyloid peptides from patient’s cerebrospinal 
fluids were isolated by immunopurification.  The samples were mixed with ampholytic buffer 
to suit for the isoelectric focusing (“1. IEF”).  Isoelectric focusing separated the β-amyloid 
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peptides according to their isoelectric point in a pH-gradient matrix.  The peptide zones were 
sampled separately with a short piece of a fused-silica capillary (“2. Sampling”), transferred, 
and deposited on one micropillar of the micropillar array (“3. Deposition”).  A photograph of 
the micropillar with a nanodroplet of the sample is shown in the inset of “3.”.  Each sample 
fraction on the micropillar array was analysed by matrix-assisted laser desorption mass 
spectrometry.  Figure 7(B) shows the isoelectric focusing enriched β-amyloid peptides (“ii”), 
which enabled the mass spectrometric identification of more β-amyloid peptide species 
compared to sample treatment using only immunoprecipitation (“i”).  
 
2.4 Genetic disorders  
The genetic disorders related to glucose-6-phosphate dehydrogenase deficiency [113], 
spinal and bulbar muscular atrophy [114], β-thalassemia [115], and von Gierke's disease 
[116] were studied using genotyping and mutation analysis combined with MGE-LIF.  
Further, the relationship of androgen receptor CAG repeat genotype to muscle strength, 
testosterone level and finger length was studied in male subjects [117].  The D-enantiomer of 
the drug penicillamine, which is administered in the therapy to treat Wilson’s disease, was 
determined using a compact and inexpensive microfluidic platform with LED-induced 
fluorescence detection [118].  Genetic disorders in dogs were also investigated and included 
collie eye anomaly [119] and neuronal ceroid lipofuscinosis [120].  
 
2.4.1 Glucose-6-phosphate dehydrogenase deficiency 
Mutations in the X-linked gene Xq2.8 are linked to the development of glucose-6-
phosphate dehydrogenase deficiency [113].  This deficiency is a predisposition for the 
spontaneous destruction of red blood cells.  Samples from 70 patients were analysed using 
restriction fragment length polymorphism and fragment size separation by MGE-LIF.  The 
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mutant fragments were of different length compared to the wild-type restriction patterns and 
could be separated and identified by MGE-LIF.   
 
2.4.2 Spinal and bulbar muscular atrophy 
Spinal and bulbar muscular atrophy and amyotrophic lateral sclerosis have similar 
symptoms and can be misdiagnosed [114].  Using CAG base repeat expansion analysis with a 
forward primer (i.e., 5’-ACCTACCGGCACCCAGAG-3’) and reversed primer (i.e., 5’-
CTCATCCAGGACCAGGTAGC-3’), 302 patient samples diagnosed with amyotrophic 
lateral sclerosis were subjected to screening analysis by MGE.  The genetic diagnosis was 
performed by detecting the expansion of a CAG repeats in the androgen receptor gene.  The 
expansion in repeats leads to differences in size that were electrophoretically separated.  In 
the 302 samples, 4 could further be diagnosed with spinal and bulbar muscular atrophy that 
was initially diagnosed with amyotrophic lateral sclerosis. 
 
2.4.3 β-thalassemia 
Specific mutations in the β-globin gene are associated with the development of β-
thalassemia, a genetic blood disorder with little to severe symptoms.  Prenatal diagnostic of 
the mutations in the β-globin is recommended for people carrying the gene since the disease 
might require long-term care.  However, invasive prenatal diagnostic has risks for mother and 
child and is recommended for high-risk groups only [121].  A standard methodology is blood 
sampling of the chorionic villi followed by DNA extraction, amplification and sequencing.  
Less invasive venous blood sampling is challenging, because of the low abundance of the 
child’s DNA (<5%) in the mother’s blood.  A peptide nucleic acid-mediated enriched PCR 
(PNA-PCR) amplification followed by MGE sequencing of the mutant and wild-type DNA 
sequences was applied to detect foetal β-globin mutations in maternal plasma [115].  The 
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PNA-PCR enabled selective inhibition of the maternal wild-type allele and to preferentially 
amplify foetal mutated sequences.  This sensitivity improving strategy was key in enabling 
prenatal diagnostic from venous blood of the mother.  41 prenatal diagnoses on maternal 
plasma were performed and compared to invasive extraction of foetal DNA from chorionic 
villi that were analysed by the standard procedure.  The results of the chip approach were in 
agreement with the standard method.  
 
2.4.4 von Gierke disease 
A disposable chip for real-time PCR and high-resolution melt analysis was developed 
and validated for the diagnostic of von Gierke disease, an inherited glycogen storage disease 
[116].  The chip made from low autofluorescence cyclic olefin thermoplastic was patterned 
with thin film metal electrodes.  The small dimension of the chip and chip material properties 
enabled very fast heating and cooling rates that were crucial for PCR.  A single PCR cycle 
was completed in 14 s and the full amplification process required 8.5 min.  Human genomic 
DNA was amplified using the G6PC primers and the obtained product was identified by on-
chip high-resolution melt analysis where the device provided accurate melting temperature 
with a variation of 0.6 % to the expected melt temperature.  The amplicons were further 
analysed by MGE-LIF.  
 
2.5 Cardiovascular diseases  
Acute myocardial infarction [122,123], coronary artery disease [124–128], and 
hypertension [129] were investigated.  
 
2.5.1 Acute myocardial infarction 
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Increased levels of serum deoxyribonuclease I have been reported in patients with 
myocardial infarction [130].  The first determination of deoxyribonuclease I using PCR 
followed by MGE-LIF was demonstrated [122].  Deoxyribonuclease I digests double-
stranded DNA to oligonucleotides.  DNA size standards of 100 and 800 bp were incubated 
with the enzyme for up to 80 min prior to the injection and size-based electrophoretic 
separation.  The MGE gel contained ethidium bromide to stain the undigested DNA.  
Digestion of the DNA resulted in a decrease in signal intensity that was correlated to the 
enzyme activity.  The detection was completed in approx. 10 min which was substantially 
faster than widely used ELISA and single radial enzyme diffusion assay that require up to 20 
hrs.  
 
2.5.2 Coronary artery disease 
Coronary artery disease as a result of atherosclerosis was investigated by determining 
the composition of lipoproteins in the blood.  The class of lipoproteins is divided into high-
density lipoprotein (HDL) and low-density lipoproteins (LDL).  The LDL are further 
subdivided into small, dense low-density lipoprotein (sdLDL), large, buoyant LDL (lLDL), 
and very low-density lipoproteins (vLDL).  The isolation of these lipoproteins is difficult and 
is commonly performed by ultracentrifugation [131].  The serum lipoprotein contents of 
patients with atherosclerosis were analysed by a workflow of ultracentrifugation, fluorescent 
derivatisation of the isolated fractions, and electrophoretic separation with fluorescence 
detection [124–128].  Off-line derivatisation was performed with 7-nitrobenz-2-oxa-1,3-
diazole-C6-ceramide.  The separation of the lipoprotein fractions was difficult because the 
analytes were prone to channel wall adsorption and the small difference in electrophoretic 
mobility further complicated the separation.  A dynamic channel coating with n-dodecyl-β-D-
maltoside and hydroxypropyl cellulose as sieving matrix was applied and resulted in partial 
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to baseline separation of the lipoproteins.  A further separation improvement was obtained 
when 5 nm diameter gold nanoparticles were added to the sample and BGS solutions.  The 
nanoparticles caused a peak focusing of the various lipoproteins types and detection was 
completed in 2.4 min.  This method was then applied to analyse 65 serum samples; 35 with 
previously diagnosed coronary heart disease and 30 healthy samples.  The concentration of 
sdLDL and vLDL in patients was higher than in healthy subjects.  Treatment of patients with 
atorvastatin, a lipoprotein-reducing drug, was shown to lower the concentrations of sdLDL 
and vLDL.  
 
2.5.3 Hypertension 
The insertion and deletion polymorphism in the angiotensin-converting enzyme gene 
is associated with hypertension.  A strategy of MGE-LIF using an electric-field gradient was 
explored for mutation detection in the Alu element of the angiotensin-converting enzyme 
gene [129].  The target DNA had a length of 190 bp and 490 bp after deletion and insertion, 
respectively.  These fragments were amplified by 10 cycles of PCR followed by the gel 
electrophoretic separation using a stepwise electric field gradient of 129 to 615 V cm-1.  Fast 
polymorphism detection was achieved in less than 25 s.  The mutation analysis was compared 
to slab-gel electrophoresis where the MGE strategy was 300-times faster.  
 
2.6 Infectious diseases  
Infections caused by viruses (i.e., hepatitis B and influenza) and bacteria (i.e., 
Escherichia coli and Staphylococcus aureus) were investigated using strategies of 
genotyping, immunoassays, and zone electrophoresis.   
 
2.6.1 Viral infections 
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Viral infections by influenza A/B and hepatitis B were studied by MGE-LIF, DEP-
LIF, and immunoassay MCE [132–134].  Influenza A subtype H1N1 was analysed by PCR 
amplification of hemagglutinin (116 bp) and nucleocapsid protein (195 bp) genes prior to the 
subsequent amplicon separation in a multichannel MGE-LIF device [132].  An electric field 
gradient and channel coating with 1% poly(vinylpyrrolidone) improved amplicon separation.  
Rapid separation (i.e., 20 s) and parallel sample analysis were achieved rendering the device 
suitable for high-throughput analysis.  Using a droplet DEP device that integrated 
multiplexed and quantitative reverse transcription PCR, influenza A and B from 
nasopharyngeal and throat swabs were analysed [133].  The sample droplets were guided by 
DEP to eight chambers for PCR amplification and subsequent fluorescence read-out.  Eight 
samples were simultaneously analysed in less than 40 min and the RNA detection limit was 
less than 10 copies per chamber.   
 
Hepatitis B was diagnosed using an immunoassay-based strategy where the enzymatic 
activity of alanine aminotransferase in patient serum samples was determined [134].  The 
determination of the enzyme activity is used as an indicator of liver cell injury such as can 
occur in hepatitis B patients.  Alanine aminotransferase reversibly converts L-alanine and α-
ketoglutarate into pyruvate and L-glutamate, respectively.  Known concentrations of pyruvate 
and L-glutamate were added to serum samples and based on the concentration change of the 
substrates, the enzyme kinetic constants could be calculated using Lineweaver–Burk plots.  
Patient’s samples showed a decrease in L-glutamate concentration compared to healthy 
subjects which were a consequence of higher levels of the enzyme. 
 
2.6.2 Bacterial infections 
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Bacterial infections were identified on a paper-based MCE device [135] and bacterial 
resistance was investigated using DEP and Raman spectroscopy [136].  Furthermore, MCE 
with electrochemical detection was applied for the determination of antibiotic drugs in 
biological samples [137,138].  For instance, the antibiotic formulation sulperazone was 
determined using a novel gold nanoparticle-modified indium tin oxide microelectrode for 
amperometric detection [137].  The deposition of particles on the flat electrode surface 
increased the surface area and improved the detection sensitivity. 
 
A paper-based MGE device was explored for the separation of characteristic 
amplicons of Escherichia coli O157:H7 (i.e., rrsH gene, 121 bp) and Staphylococcus aureus 
(glnA gene, 225 bp) [135].  The T-shaped microfluidic structures were written by a plotter 
and sandwiched between layers of overhead projector covers and adhesive films.  The sample 
reservoirs were made from PDMS.  The pathogen DNA was extracted from cell culture and 
amplified using a benchtop PCR thermal cycler followed by fluorescence labelling.  The 
device that was fabricated at material costs of less than US$ 2 separated the amplicons in less 
than 3 min and was sensitive to detect as little as 9.3×101 copies (or 0.5 pg) of target DNA.  
 
An antibiotic resistance test for Escherichia coli was demonstrated on a microfluidic 
platform that applied cell sorting by DEP and single cell read-out by Raman spectroscopy 
[136].  Blood samples from sepsis patients were collected and cultivated.  The cultured 
bacteria were treated with different concentration of the antibiotic ciprofloxacin.  DEP was 
used to trap single cells in the Raman laser focus for spectrum acquisition.  The changes in 
Raman peaks and peak profile correlated with antibiotic resistance of the bacteria and were 
used to determine the minimal inhibitory concentration.  The results were obtained in 2 h and 
were in agreement with reference methods (i.e., broth microdilution, Vitek-2, E-test).   
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2.7 Organ diseases and dysfunctions  
The approaches to study the function of liver [139], kidney [140–143], lacrimal gland 
[144,145], and thyroid gland [146] included miniaturised immunoassays, gel electrophoresis, 
and zone electrophoresis.  
 
2.7.1 Liver dysfunction  
Liver dysfunction in infants with hyperbilirubinemia was investigated by 
immunoassay and frontal analysis chip electrophoresis to determine the free bilirubin in 
serum [139].  The immunoassay was applied to determine the binding constant of bilirubin 
with human serum albumin which then could be used to calculate the free bilirubin based on 
the total bilirubin and the binding constant.  The measurement of the free bilirubin in the 
serum of neonates has been recognised as a reliable indicator to predict the toxicity of 
hyperbilirubinemia [147,148].  
 
2.7.2 Kidney function 
Kidney function was evaluated based on measuring the urea concentration in human 
serum [140], creatinine and protein concentration in urine [142,143] and artificial human 
serum [141].   
 
An indirect detection of urea was applied by determining the ammonium ion, the 
enzymatic reaction product of urea in the presence of urease [140].  The serum samples were 
incubated with urease which resulted in the production of the ammonium ion.  After this 
enzymatic conversion, the sample was injected and the ammonium ion was quantitated using 
contactless conductivity detection.  Creatinine in human urine was determined by MCE with 
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LED-induced fluorescence detection [141].  To remove particulate matter, the urine was 
centrifuged and filtrated before the analyte derivatisation with FITC.  The detection of the 
baseline separated analytes was achieved in 30 s using a LED induced excitation at 490 nm 
and emission detection at 523 nm.  This method was evaluated as an alternative for standard 
Jaffe’s colourimetric assay and provided results concordant with the colourimetric assay.  
Creatinine and albumin were also determined using pencil-drawn graphite electrodes used in 
electrochemical detection [143].  This method provided baseline separation of the two 
analytes in less than 2 min with migration time reproducibility of >2% RSD.  The obtained 
detection sensitivities were 20 and 35 µM which were relevant for clinical diagnostics.   
 
A urine protein profiling method was based on MCE-UV [33].  To avoid the proteins 
of adhering to the channel wall, a BGS of 75 mmol L-1 borate buffer containing 0.8 mmol L-1 
calcium lactate and 1% ethylamine at pH 10.55 was applied.  Model proteins human albumin 
and human transferrin were detected at detection limits of 1.5 g L-1.  The method was then 
evaluated on 248 pre-treated urine samples and the results were consistent with the standard 
American Helena agarose gel electrophoresis methodology.  However, the agarose gel 
electrophoresis required 45 min while the chip-based strategy was completed in 4 min.  
 
2.7.3 Lacrimal gland 
Lacrimal gland function was studied by analysing the inorganic ion composition of 
human tear samples [145] and the effect of intravenously administered pituitary adenylate 
cyclase activating polypeptide (PACAP) on the tear and endolymph protein composition in 
rats and chicken [144].  The inorganic ions sodium and potassium are the main electrolyte in 
tear fluid and these ions are relevant in osmotic regulation and corneal epithelium 
maintenance.  A cost-efficient microfluidic platform based on poly(methyl methacrylate) 
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cross-channel chip with pencil drawn graphite electrodes for contactless conductivity 
detection was applied for separation and detection of sodium and potassium in 2 min with 
detection sensitivities <6.8 µM.  PACAP was administered to the rats and chicken prior to the 
sampling of the tear and endolymph using sterile absorbent paper strips.  The sample was 
eluted from the filter strips into a denaturing buffer for the followed MGE.  While the protein 
composition in the endolymph of chicken did not observably change due to peptide injection, 
the tear composition in rats changed.  The peptide injection affected the protein profile of 
proteins in the molecular mass range of 50 to 70 kDa.   
 
2.7.4 Thyroid gland 
Thyroid gland function was investigated by chemiluminescence immunoassay of 
thyroxine in human plasma [146].  In the competitive immunoassay, the sample was 
incubated for 15 min with a known amount of HRP-labelled analyte and low concentration of 
anti-thyroxine antibody.    The electrophoretic separation resulted in two signal peaks; one for 
the HRP-labelled analyte and HRP-labelled analyte-antibody complex.  The unknown analyte 
in the sample competed with the HRP-labelled counterpart for binding with the antibody. 
This competition caused a change in the peak ratio that could be used to indirectly quantify 
thyroxine.  Detection of the two peaks was in less than 1 min and afforded a low-nM 
sensitivity. 
 
2.8 Diabetes and pancreatic dysfunction  
Diabetes mellitus and diabetic complications [149–152], and acute pancreatitis [153] 
were studied by chip immunoassay and MGE-LIF.   
 
2.8.1 Diabetes 
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Diabetes mellitus was studied by the analysis of haemoglobin-A1c, urinary proteins, 
and human insulin-like growth factor-I.  The determination of hemoglobin-A1c in the blood 
can be used to assess the average three-month glucose concentration.  Using an on-chip 
sandwich immunoassay, the fraction of hemoglobin-A1c in total haemoglobin of human 
blood was determined [149].  The assay used antibody-conjugated magnetic nanoparticles 
that were prepared from layers of Au/chitosan/Fe3O4.  The anti-human hemoglobin-A1c 
antibody-functionalised magnetic beads were injected from one chip reservoir and 
immobilised in the device channel by a magnetic field.  From another reservoir, the sample 
was injected and incubated for 8 min with the immobilised particles.  After a washing step to 
remove any unbound sample, a solution of secondary anti-human haemoglobin antibody was 
incubated for 6 min.  This secondary antibody bound to the captured analytes.  The sandwich 
assay was completed by an incubation step with alkaline phosphatase conjugated goat anti-
rabbit antibody that bound to the secondary antibody.  The substrate solution (i.e., 1-naphthyl 
phosphate) was then added to the sample reservoir and a substrate plug was injected to 
separation channel.  Upon application of separation voltage, the substrate plug passed the 
immobilised alkaline phosphatase where the conversion from 1-naphthyl phosphate to the 
electrochemically-active 1-naphtol occurred.  The analysed blood samples (after blood 
haemolysis) had a fraction of hemoglobin-A1c in the range of 4.84 to 10.31%.  Although the 
assay platform provided the analytical result within 30 min, several assay parameters (e.g., 
particle synthesis, particle incubation time, and magnetic field) have to be carefully optimised 
and controlled.  
 
The urinary proteins transferrin, β2-microglobulin, human serum albumin, and 
immunoglobulin G are biomarkers used in the evaluation of the kidney and urinary tract 
function of diabetes mellitus and diabetic nephropathy patients.  An integrated microfluidic 
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platform for sample clean-up, enrichment and detection of the four urinary proteins was 
demonstrated [150].  Sample clean-up and enrichment was performed by transient 
isotachophoresis.  Transient isotachophoresis could tolerate the high ionic strength urine 
samples without requiring additional sample clean-up and also provided a sample enrichment 
of factor 40 that supported sensitive analysis.  The microchip was conditioned with leading 
electrolyte (i.e., Tris-HCl) followed by the sample injection.  The terminating electrolyte (i.e., 
acetic acid) was added to the inlet buffer reservoir after sample injection and the 
electrophoretic process was started.  The device provided concordant results with common 
radio-immunoassay but was completed in 10 min compared to the 7 h required in the radio 
immunoassay.   
 
Human serum albumin in urine samples of 48 diabetes patients was analysed by 
MGE-LIF and compared to standard immunoturbidimetry measurement [151].  For MGE-
LIF, the albumin in the urine sample was first heat denatured, diluted and spiked with an 
internal standard (i.e., chicken albumin) prior to the sample loading into the chip reservoir.  
The sieving gel matrix contained a fluorescence dye for on-chip labelling of the analyte.  
Interestingly, MCE detected higher levels of albumin (mean = 167.5 mg L-1) compared to 
immunoturbidimetry (mean = 98.2 mg L-1) which was attributed to the ability of MCE to 
measure immuno-reactive albumin which remains undetected by turbidimetry.   
 
Sensitive detection of human insulin-like growth factor-I (IGF-I ) in serum was 
demonstrated in a competitive immunoassay followed by stacking MCE [152].  Stacking was 
by field-amplified sample stacking which was implemented by the preparation of the pre-
treated serum samples in a low conductivity matrix.  The reconstitute was incubated with a 
known concentration of mouse anti-human IGF-I monoclonal antibody for 30 min at 37 ºC 
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before the addition of a known concentration of fluorescently labelled green fluorescence 
protein–IGF-I.  The detected concentration of the unbound labelled green fluorescence 
protein–IGF-I was inversely proportional to the analyte concentration.  Stacking afforded an 
enrichment of the free fluorescent IGF-I of three orders of magnitude and the assay provided 
a detection sensitivity of 0.68 ng mL-1. 
 
2.8.2 Acute pancreatitis 
Acute pancreatitis was analysed by the determination of pancreatic α-amylase activity 
using immunoassay MGE-LIF [153].  A fluorescence labelled oligosaccharide was applied as 
a substrate for the amylase-mediated enzymatic conversion.  The sample and label were 
mixed offline and allowed to react for 0-160 min.  In order to exclusively determine the 
pancreatic α-amylase unbiased from the presence of salivary amylase, a salivary amylase 
inhibitor was added.  The enzymatic activity was measured as the increase in the peak of the 
formed enzymatic product (i.e., oligosaccharide hydrolysate) after electrophoretic separation 
of the substrate from the enzymatic product.  The use of borate in the sieving matrix (i.e., 
sieving BGS was 0.5% methylcellulose in 0.2 M borate buffer at pH 8.5) resulted in 
complexation and conformational changes of the substrate that improved separation.  This 
method enabled the determination of pancreatic amylase in the range of 5-500 U L-1 with a 
limit of detection of 4.38 U L-1.  The analysis of 13 plasma samples showed pancreatic 
amylase concentrations in the range of 13 to 74 U L-1. 
 
2.9 Reproductive disorders  
Reproductive disorders were investigated by the study of androgen disorders in male 
subjects [154], monitoring the female reproductive system [155], and detection of preterm 
biomarkers [156,157]  
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2.9.1 Androgen and progesterone related disorders  
Serum concentrations of testosterone in men and progesterone in women were 
determined using a competitive immunoassay format with highly sensitive 
chemiluminescence detection [154,155].  Both hormones are biologically important and serve 
as a biomarker for reproductive disorders.  The off-line competitive immunoassay for the two 
hormones was performed by mixing the sample with a known amount of HRP-labelled 
hormone and anti-hormone antibody.  The unlabelled hormone in the sample and the added 
label competed for binding with the antibody.  A gradual decrease in peak intensity of the 
label was obtained as a consequence of the hormone in the sample.  The subsequent 
electrophoretic separation was required to separately detect the free label and the hormone-
antibody complex.  The chemiluminescence signal was triggered by luminol, HRP, and 
hydrogen peroxide.  The limit of detections for progesterone and testosterone were 3.8 nM 
and 1 nM, respectively.  Progesterone concentrations of <46 nM in controls and >413 nM 
pregnant women were determined.  Testosterone concentration in men was found in the range 
of 14 to 24 nM.  
 
2.9.2 Preterm birth  
The birth of babies before the 37th week of pregnancy is considered preterm birth and 
is a leading cause of complication during pregnancy.  The risk of preterm birth has been 
predicted by a panel of peptide biomarkers in serum [158].  One of these preterm peptide 
biomarkers is a 19 amino acid long and proline-rich peptide that was determined in fortified 
serum samples using a microfluidic device [156,157]. The device integrated sample 
extraction (i.e., solid-phase extraction), fluorescence derivatisation, and separation of the 
biomarker.  The biomarker was spiked in diluted serum samples and subjected to solid-phase 
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extraction that was embedded in the microfluidic channel.  The extraction material could 
tolerate the presence of 5% serum in the sample solution, however, the extraction yield 
significantly decreased at this serum concentration.  A 15-fold enrichment of the biomarker 
was achieved which afforded a detection limit of 50 nM.  
 
Outlook and challenges 
In the last decade, MCE has become an established analytical platform that has 
influenced today’s clinical environment.  While in the early 2000s MCE was in a stage where 
the main driver was on fabrication and proof-of-concept studies, MCE underwent a transition 
that enabled the integration of a whole analytical workflow or truly “lab-on-a-chip”.  
Although fast (sub)-min separation times were already achieved in the 1990’s, the rapidly 
advancing fields of lab-on-a-chip and MCE provided ingenious solutions and methods that 
were pivotal to the study of biomarkers.  For instance, MCE has become an enabler in the 
study of single entities (e.g., single cell analysis) where delicate manipulation and 
interrogation of the single entity could be performed using purpose-built fluidic structures, 
efficient separation, and sensitive detection.  However, there are still challenges that hinder 
the full promise of lab-on-a-chip.   
 
The microfluidic chips were mainly used as the separation platform – an inherent 
advantage of electrophoresis where a weightless electric field and micrometre-sized fluid 
filled channels are all that is required for separation.  Sample preparation, fluidic control, and 
detection within the MCE devices are however relevant areas that need to be improved.  Most 
of the reviewed approaches relied on traditional benchtop equipment such as syringe pumps, 
solenoid valves, spectrometers, and microscopes.  The operation of this specialised 
equipment also required skilled staff.  A plausible avenue to address these issues is the 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
45 
 
miniaturisation of the auxiliaries and a simplification of the analytical workflow.  There were 
demonstrations of “sample-in-answer-out” platforms that made use of compact optical and 
electrochemical detection and reduced the number of auxiliaries.  Another bottleneck is the 
fabrication of MCE devices, which generally involves a multidisciplinary team of highly 
trained personnel and a long sequence of fabrication steps.  A simplification of the fabrication 
process would support the spread and wider acceptance of MCE for diagnostics.  Promising 
solutions to fabricate (disposable) microfluidic chips at relatively low cost include paper-
based and polymer-based platforms that can be mass-produced.   
 
Today’s diagnostic is generally performed in dedicated centres, which requires an 
efficient sample transport system from place of sampling (e.g., doctor’s office) to the centre.  
This is not only intensive in logistics but also reduces the frequency of possible sampling and 
diagnostic testing.  For preventive care and early disease detection, however, frequent testing 
is crucial.  Making the diagnostic test easily accessible for both the health professionals and 
person to be tested would support the efforts for disease prevention and cure.  MCE has the 
potential for on-site diagnostics and could serve as a “generic” platform for the development 
of novel assays for treatment monitoring at home.  However, to truly realise this promise, 
more efforts should be geared towards the translation from the research laboratory into the 
clinical setting and ultimately to the end users’ home.  The translation should result in 
validated “sample-in-answer-out” procedures that can be performed by traditionally trained 
clinical chemists who will be able to analyse the results rapidly for the medical doctors to 
use.  Although this is a difficult step, the route to the successful device translation will 
provide new opportunities and advance the field of MCE.  In the end, the development of 
disease-specific and validated MCE methodologies and in an easy to use small benchtop 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
46 
 
device will be attractive to end users or clinical analytical chemists whose main objective is 
only to obtain patient data for medical doctors to suggest appropriate treatment.  
 
Conclusion 
MCE in clinical diagnostic was commonly used for genotyping, mutation analysis, 
immunoassays, and small molecule detection.  The MCE approaches provided advantages in 
assay speed and flexibility compared to the traditional non-miniaturised techniques.  
Sensitive on-chip biomarker detection was demonstrated by using sensitive detectors and 
dedicated on- and off-line sample preconcentration strategies.  However, due to the small 
sample injection volumes, the detection limits were similar or inferior to established 
methodologies.  Genotyping and mutation analysis was applied to diagnose inherited diseases 
and to investigate the effect of environmental factors on the genetic make-up.  Mutation 
analysis in cancer samples was most common.  Genotyping and mutation analysis of nucleic 
acid samples was performed by MGE-LIF after target amplification by PCR.  The microchip 
format provided significant advances in speed and base pair resolution (e.g., single base pair 
resolution) compared to the traditional slab gel electrophoresis.  PCR was generally 
performed using commercial off-line benchtop instrument while on-chip PCR was infrequent.  
Technical challenges including probe adsorption on fluidic walls, sample evaporation, and 
temperature control which might have been some of the reasons that hampered wider 
integration of on-chip PCR.  Immunoassays were applied for activity and concentration 
measurements of proteins and peptides in circulating biological fluids.  This was clinically-
relevant in the diagnosis and treatment of cancer, immune disorders, infectious-, 
neurological-, and reproductive diseases.  In these immunoassays, the immuno-specific 
interaction of antibody and antigen was performed on- and off-chip prior to the 
electrophoretic separation of the free label and labelled target complex.  The two main 
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detection approaches were LIF and chemiluminescence.  For chemiluminescence, an 
additional channel for delivery of luminescence reagents was integrated on the chip before 
the detection point.  
 
Small molecules and inorganic ions were separated by zone electrophoresis with 
absorbance and electrochemical detection.  These analytes were drugs quantified in blood and 
blood-derived samples after adequate sample preparation.  The on-chip implementation of 
compact electrochemical detectors enabled the fabrication of point-of-care device for lithium 
detection in whole blood.  This example reflects what it is probably the most significant 
contribution of MCE to clinical diagnostics: the merge and match of the advances in 
microfabrication with powerful and compact electrophoretic separation.  The advances in 
microfabrication made it possible to fabricate chips with purpose-built structures for 
diagnostics.  However, qualitative and quantitative diagnosis on a miniaturised chip generally 
relies on a highly efficient separation step in order to achieve analyte separation in the 
smallest channel dimensions.  This is where electrophoresis as an ideal match to complete the 
diagnostic device found its application.  At its core, electrophoresis only requires an electric 
field and supporting media to achieve separation and this is relatively unaffected by the small 
dimensions of the chip.  Retrospectively, MCE has enriched the diagnostic field in the last 
decade and enabled high-speed analysis requiring only smallest sample sizes that were in 
favour of both the patients and clinicians.   
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Table 1. MCE applied for different diseases. 
Disease Biomarker 
type 
Biomarker Sample Off-line sample 
preparation 
Separation 
time 
Separation 
and detection 
Sensitivity (or 
sample 
requirement) 
Focus Ref 
(i) Cancer 
Breast cancer Cells 
Human breast 
cancer cell line 
MCF7 
Model 
cell line n/a n/a DEP-LIF n/a 
Microarray for 
anticancer drug 
screening 
[54] 
Renal cancer RNA 
Total RNA from 
renal cell 
carcinoma  
Human 
tissue 
RNA extraction 
and PCR n/a MGE-LIF n/a 
RNA stability 
analysis [58] 
General cancer 
marker DNA 
Telomerase 
activity 
Model 
cell lines 
Target extraction 
and PCR < 5 min MGE-LIF 5 cells 
Telomeric repeat 
amplification analysis [60] 
General cancer 
marker DNA 
Telomerase 
activity 
Model 
cell lines 
Target extraction 
and PCR 2 min MGE-LIF 1 cell 
Telomeric repeat 
amplification analysis [61] 
General cancer 
marker Protein Carcinoembryo
nic antigen 
Human 
serum 
Aptamer-based 
target 
amplification 
1.5 min MGE-LIF 68 pg ml-1 Aptamer-based 
assay [62] 
General cancer 
marker Protein 
Carcinoembryo
nic antigen 
Human 
serum 
n/a < 2 min MCE-LIF 45.7 pg ml-1 Non-competitive immunoassay [63] 
General cancer 
marker Enzyme 
Thymidine 
kinase 1 
Standar
ds none 20 s MGE-LIF 2 µg mL
-1
 Immunoaffinity assay [64] 
General cancer 
marker DNA 
Exons 5–9 of 
p53 gene 
Human 
tissue 
Target extraction 
and PCR 6 min MGE-LIF n/a 
Single strand 
conformational 
polymorphism and 
heteroduplex 
analysis 
[67] 
Lung cancer DNA 
EGFR exon 19 
and 21 
alterations 
Human 
tissue  
Target extraction 
and PCR <2 min MGE-LIF 
5% of mutated 
alleles in the 
presence of 95% 
wild-type alleles 
fragments 
EGFR gene 
mutations [68] 
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Lung cancer DNA 
EGFR exon 19 
and 21 
alterations 
Human 
tissue  
Target extraction 
and PCR n/a MGE-LIF 
5% mutant 
fragment in 95% 
wild-type 
EGFR gene 
mutations [69] 
Lung cancer Enzyme 
Neuron-
specific 
enolase 
Human 
serum 
n/a 1 min MCE-CL 4.5 pM Competitive enzyme immunoassay [70] 
Blood cancer DNA 
Variable region 
in the T-cell 
receptor γ 
gene 
Canine 
blood 
Target extraction 
and PCR <10 s MGE-LIF n/a 
Rapid diagnostic of 
T-cell lymphoma [71] 
Blood cancer DNA 
Variable 
number of 
tandem repeat 
markers 
D1S11, YNZ, 
D1S80, and 
ApoB 
Human 
blood 
and cord 
blood 
Target extraction 
and PCR ~3 min MGE-LIF  0.02 ng DNA 
Assay for post-
hematopoietic stem 
cell transplantation 
chimerism monitoring 
[72] 
Blood cancer DNA Bcl-2/IgH fusion gene 
Human 
blood 
and 
tissue 
Target extraction 
and PCR 2 min MGE-LIF n/a 
Identification of 
fusion sequences in 
follicular lymphoma  
[73] 
Blood cancer DNA Ig heavy chain gene 
Human 
tissue 
Target extraction 
and PCR n/a MGE-LIF 
10% target DNA in 
90% non-target 
DNA 
B-cell clonality 
analysis [74] 
Blood cancer DNA Calreticulin gene 
Human 
bone 
marrow 
and 
peripher
al blood 
Target extraction 
and PCR n/a MGE-LIF n/a 
Mutation analysis in 
myeloproliferative 
neoplasms 
[76] 
Colorectal 
cancer 
DNA KRAS codon 12 mutation 
Human 
tissue 
Target extraction 
and PCR 5 min MGE-LIF 
0.01% target DNA 
in non-target DNA 
Mutation detection 
using restriction 
fragment length 
polymorphism 
[77] 
Colorectal 
cancer 
DNA 
Microsatellite 
loci Bat25, 
Bat26, 
D2S123, 
D5S346 and 
Human 
tissue 
DNA extraction 
and PCR <2 min MGE-LIF n/a 
Analysis of 
microsatellite 
instability in 
colorectal carcinoma 
[78] 
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D17S250 
Colorectal 
cancer 
Polysacchari
de N-glycans 
Human 
serum 
Denaturation, 
disulfide bond 
reduction, 
digestion, glycan 
isolation by solid-
phase extraction, 
derivatisation 
2 min MGE-LIF n/a N-glycan profiling [79] 
Prostate cancer DNA GSTP1 and RARB2 gene 
Human 
blood 
Target extraction 
and PCR 2.5 min MGE-LIF n/a 
Analysis of 
circulating free DNA 
in response to 
chemotherapy 
[81] 
Oral cancer DNA 
13 genes 
(ECAD, RARβ, 
TMEFF2, 
MGMT, DAPK, 
p15, p16, 
TIMP3, FHIT, 
HIN-1, 
SPARC, APC, 
WIF) 
Human 
oral 
rinse 
Target extraction 
and PCR n/a MGE-LIF n/a 
Analysis of aberrant 
DNA methylation in 
squamous cell 
carcinoma 
[82] 
Liver (and 
colorectal) 
cancer 
Proteins 
Carcinoembryo
nic antigen and 
α-fetoprotein 
Human 
serum 
None 1 min MCE-EC 0.25 and 0.13 ng 
mL-1 
Non-competitive 
immunoassay [83] 
Liver cancer Protein α-fetoprotein Standard None <3 min ITP-MGE LIF 5 pM 
Sensitive 
immunoassay 
strategy 
[84] 
Liver cancer Protein α-fetoprotein-L3 
Human 
serum 
n/a 2.5 min MCE-LIF 0.3 ng mL-1 
Non-competitive 
immunoassay for 
hepatocellular 
carcinoma 
[85] 
Liver cancer Protein 
α-fetoprotein 
and des-γ-
carboxy 
prothrombin 
Human 
serum 
n/a n/a MCE-LIF n/a 
Chip-based liquid-
phase binding assay 
for hepatocellular 
carcinoma 
[86] 
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Liver cancer Protein 
α-fetoprotein-
L3 (AFP-L3) 
and 
prothrombin 
induced by 
vitamin K 
absence-II 
(PIVKA-II) 
Human 
serum 
n/a n/a MCE-LIF  
0.3 ng mL-1 AFP-
L3 and 5 AU/L 
PIVKA-II 
Evaluation of the 
diagnostic value of 
combined AFP-L3 
and PIVKA-II 
detection for 
hepatocellular 
carcinoma 
[87] 
Ovarian cancer Polymer N-glycans Human 
serum 
Denaturation, 
disulfide bond 
reduction, 
digestion, glycan 
isolation by solid-
phase extraction, 
derivatisation 
1.5 min MCE-LIF n/a N-glycan profiling [88] 
Cervical cancer DNA 
Human 
papillomavirus 
DNA 
PGMY09/11 
Human 
tissue 
Target extraction 
and PCR 4 min MGE-LIF 2 x 10
2
 copies 
Genotyping by 
restriction fragment 
length polymorphism 
[89] 
Cervical cancer RNA 
Human 
papillomavirus 
E6/E7 mRNA 
Model 
cell line 
Target extraction 
and PCR 1.5 min MGE-LIF 1 cell 
Comparison of three 
amplification 
techniques in 
combination with 
MGE 
[90] 
Ovarian cancer Protein 
β-subunit of 
human 
chorionic 
gonadotropin 
Human 
serum 
None 1 min MCE-CL 0.36 mIU mL-1 Non-competitive immunoassay [91] 
Bladder cancer Protein/Enzy
me 
Galectin-1 and 
lactate 
dehydrogenas
e B 
Model 
cell line 
Cell lysis, 
derivatisation 60 min DEP-LIF n/a 
Multiplexed 
immunosensor for 
protein expression 
analysis 
[92] 
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Bladder cancer Cells 
Human 
bladder cancer 
cells 
TSGH8301 
Model 
cell line n/a ~2 min DEP Single cell 
Controlled trapping 
and release of single 
cells 
[93] 
Bladder cancer DNA 
FGFR3, TERT, 
HRAS, ALX4, 
RALL3, MT1A, 
and RUNX3 
genes 
Artificial 
human 
urine 
Target extraction 
and PCR 2 min MGE-LIF 5 cells 
DNA mutation 
analysis for bladder 
cancer diagnostic 
[94] 
(ii) Immune disorders 
Inflammation 
Protein and 
small 
molecule 
3-nitrotyrosine, 
thyroxine, and 
C-reactive 
protein 
Standar
ds None 2 min MCE-LIF 0.3 to 5 µg mL
-1
 
Cleavable tag 
immunoassay [95] 
Inflammation Protein C-reactive protein 
Human 
serum 
Immunoprecipitati
on 
30 s MGE-LIF 126 pg µL-1 
Sensitive target 
detection from 50 µL 
sample 
[96] 
Inflammation Proteins 
Interleukin 6, 
gamma 
interferon, 
tumour 
necrosis factor 
alpha 
Human 
skin 
biopsies 
Tissue extraction 2.5 min MCE-LIF 0.5 pg mL-1 Receptor affinity disks [97] 
Inflammation Proteins 
6 chemokines 
(CXCL1, 
CXCL5, 
CXCL8, CCL1, 
CCL3, and 
CCL5 
Human 
skin 
biopsies 
Tissue extraction 2.5 min MCE-LIF 0.2 pg mL-1 Receptor affinity disks [98] 
Inflammation Proteins 
6 chemokines 
(CCL2, CCL19, 
CCL21,CXCL8, 
CXCL12, and 
CXCL-13) 
Human 
cerebral 
spinal 
fluid 
Dilution 2 min MCE-LIF 0.5 pg mL-1 Chip-based immunoaffinity assay [99] 
Hypersensitivity DNA 
Genes 
VKORC1 and 
CYP2C9  
Prepurifi
ed 
human 
genomic 
DNA 
none 2 min MGE-LIF n/a 
On-chip genotyping 
of warfarin 
hypersensitivity 
[100] 
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Hypersensitivity DNA 
Genes 
VKORC1 and 
CYP2C9 
Human 
blood 
and 
saliva 
none ~15 min MGE-LIF 0.5 µL raw sample 
“Sample-in–answer-
out” genotyping 
device 
[101] 
Arthritis Metabolite Lactate 
Human 
synovial 
fluid 
Protein 
precipitation, 
centrifugation, 
evaporation 
40 s MCE-EC 6.5 µM Method development [102] 
Gout Metabolite Uric acid Human 
urine Dilution 90 s MCE-EC 4 µM Method development [103] 
(iii) Neurological diseases 
General 
neurological 
function 
Protein 
Cystatin C and 
general protein 
profile 
Human 
serum 
and 
cerebros
pinal 
fluid  
n/a <1 min MGE-LIF n/a Protein profiling [104] 
Epilepsy Small 
molecules Phenobarbital 
Human 
plasma 
Liquid-liquid 
extraction 50 s MCE-LIF 3.4 nM 
Competitive 
immunoassay [105] 
Epilepsy Small 
molecules 
Phenobarbital 
(and 
carbamazepine
, phenytoin, 
theophylline   
Human 
serum 
none 45 s MCE-LIF 1.8 nM 
Multiplexed 
competitive 
immunoassay 
[106] 
Bipolar disorders Small 
molecule Li
+
 
Human 
serum, 
blood, 
and 
urine. 
Bovine 
venous 
blood 
None 30 s MCE-EC ~0.09 mM Point-of-care device [107] 
Bipolar disorders Small 
molecules 
Li+, NH4+, K+, 
Na+, Ca2+, 
Mg2+, Cl−, 
NO3−, SO42−, 
PO43- 
Human 
serum 
and 
urine 
Dilution <50 s MCE-EC 1 to 7.5 µM 
Fast determination of 
inorganic ions in body 
fluids 
[108] 
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Alzheimer Protein α- synuclein 
PC12 
cells 
and rat 
brain 
tissue  
n/a n/a IEF-MCE-LIF n/a Study of protein 
aggregation [109] 
Alzheimer Peptides 
β-amyloid 
peptides 1–37, 
1–39, 1–40, 
and 1–42 
Human 
cerebros
pinal 
fluid 
None 2 min MCE-LIF n/a 
On-chip 
immunocapture, 
enrichment, and 
separation 
[110] 
Alzheimer Peptides 
β-amyloid 
peptides 1–30 
to 1–42 
Human 
cerebros
pinal 
fluid 
Immunopurificaito
n 
10-15 min IEF-MS n/a 
Enrichment of nL-
samples and MS 
identification 
[111] 
Alzheimer Small 
molecule 
Na+ ,K+, Ca2+, 
and Mg2+ 
PC 12 
cells 
Derivatisation and 
cell lysis 1 min MCE-LIF 0.003 to 0.316 fM Single cell analysis [112] 
(iv) Genetic disorders 
Glucose-6-
phosphate 
dehydrogenase 
deficiency 
DNA 
Glucose-6-
phosphate 
dehydrogenase 
gene 
Human 
blood 
Target extraction 
and PCR 2 min MGE-LIF 
1 µL of restricted 
DNA (~0.1 ng µL-
1) 
Mutation detection 
using restriction 
fragment length 
polymorphism 
[113] 
Spinal and 
bulbar muscular 
atrophy 
DNA Androgen 
receptor gene 
Human 
serum 
Target extraction 
and PCR n/a MGE-LIF n/a CAG repeat analysis  [114] 
β-thalassemia DNA β-globin gene Human blood 
Target extraction 
and PCR n/a MGE-LIF n/a 
Non-invasive prenatal 
diagnostic [115] 
von Gierke's 
disease DNA G6PC gene 
Standar
ds None n/a MGE-LIF n/a 
Disposable chip for 
qPCR and high 
resolution melt 
analysis 
[116] 
Skeletal muscle 
function DNA 
Androgen 
receptor gene 
Human 
blood 
Target extraction 
and PCR ~3 min MGE-LIF n/a 
Determination of 
CAG repeat 
polymorphisms in 
relation to skeletal 
muscle performance 
[117] 
Wilson’s disease Small 
molecule Penicillamine 
Standar
d Derivatisation 2.5 min MCE-LIF 1.1 µmol L
−1
 
Use of light emitting 
diode for LIF [118] 
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Collie eye 
anomaly DNA 
Intron 4 in 
NHEJ1 gene 
Canine 
blood 
and 
saliva 
Solid-phase 
extraction using 
filter cards 
~3 min MGE-LIF n/a Rapid genotyping [119] 
Neuronal ceroid 
lipofuscinosis DNA 
Exon 4 in 
CLN5 gene 
Canine 
blood 
and 
saliva 
Target extraction 
and PCR 3 min MGE-LIF n/a Rapid genotyping [120] 
(v) Cardiovascular diseases 
Coronary heart 
disease Protein 
C-reactive 
protein 
Human 
serum 
Dilution 10 s MCE-LIF 0.3 mg L-1 On-chip immunoassay [123] 
Myocardial 
ischemia Enzyme 
Deoxyribonucle
ase I 
Standar
ds None ~10 min MGE-LIF n/a 
Determination of 
enzyme activity [122] 
Coronary heart 
disease and 
atherosclerosis 
Protein High-density lipoproteins 
Human 
serum 
Centrifugation, 
derivatisation 3 min MGE-LIF n/a 
Rapid separation of 
subclasses of high-
density lipoprotein 
[124] 
Atherosclerosis Protein 
Lipoproteins 
(high-density 
and low 
density) 
Human 
serum 
Derivatisation 2.5 min MCE-LIF n/a 
Improving lipoprotein 
separation using gold 
nanoparticles for 
separation 
[125] 
Atherosclerosis Protein 
Lipoproteins 
(high-density 
and low 
density) 
Human 
serum 
Derivatisation 3 min MCE-LIF 5-15 µg L-1 Non-competitive immunoassay [126] 
Coronary heart 
disease and 
atherosclerosis 
Protein 
Lipoproteins 
(high-density 
and low 
density)  
Human 
serum 
Centrifugation, 
derivatisation 3 min MCE-LIF n/a 
Alternative method to 
enzymatic assays [127] 
Coronary heart 
disease and 
atherosclerosis 
Protein 
Lipoproteins 
(high-density 
and low 
density)  
Human 
serum 
Centrifugation, 
derivatisation 3 min MGE-LIF n/a 
Method development 
for lipoprotein 
separation 
[128] 
Hypertension DNA 
Angiotensin-
converting 
enzyme gene 
Human 
blood 
Target extraction 
and PCR 25 s MGE-LIF n/a 
Use of an electric-
field gradient for fast 
genotyping 
[129] 
(vi) Infectious diseases 
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Influenza A DNA Hemagglutinin 
and 
nucleocapsid 
protein gene 
H1N1 
virus 
DNA 
sample 
Target extraction 
and PCR 
20 s MGE-LIF n/a High-throughput 
screening for H1N1 
virus 
[132] 
Influenza A and 
B 
RNA Matrix gene 
and non-
structural gene 
Nasal 
and 
throat 
swaps 
Target extraction n/a DEP-LIF 10 RNA copies 
(per 5µL) 
On-chip reverse 
transcription PCR 
[133] 
Hepatitis B Enzyme Alanine 
aminotransfera
se  
Human 
serum 
Derivatisation 3 min MCE-LIF 0.2-0.4 µM Study on alanine 
aminotransferase 
activity 
[134] 
Bacterial 
infection 
DNA rrsH and glnA 
genes 
Model 
cell line 
Target extraction 
and PCR 
3 min MGE-LIF 
 
9.3×101 to 
1.6×102 copies 
Paper-based device 
for pathogen 
detection 
[135] 
Bacterial 
infection 
Bacteria E. coli Human 
blood 
Cell culture n/a DEP-Raman 
spectroscopy 
n/a On-chip antibiotic 
resistance test 
[136] 
Bacterial 
infection 
Small 
molecules 
p-aminophenol, 
o-aminophenol 
and m-
aminophenol 
Standar
ds 
None 1.5 min MCE-ED 0.24 to 0.42 µM Amperometric 
detection with gold 
nanoparticle-modified 
indium tin oxide 
electrodes 
[137] 
Bacterial 
infection 
Small 
molecule 
Vancomycin Human 
plasma 
Protein 
precipitation, 
centrifugation, 
evaporation 
3 min MCE-EC 1.2 µg mL-1 On-chip Stacking for 
sensitive vancomycin 
determination 
[138] 
(vii) Organ diseases and dysfunctions 
Renal 
insufficiency 
Protein and 
metabolite 
Albumin and 
creatinine 
Standar
ds 
None 2 min MCE-EC 20 and 35 µM Disposable paper-
based device 
[143] 
Renal 
insufficiency 
Small 
molecule 
NH4+ Human 
blood 
and 
serum 
Dilution 1 min MCE-EC n/a Monitoring of 
enzymatic reactions 
[140] 
Renal 
insufficiency 
Metabolite Creatinine Human 
urine 
Centrifugation, 
filtration, 
derivatisation 
30 s MCE-LIF 2.9 µM Method development [141] 
 
Renal 
insufficiency 
Protein Human 
transferrin and 
human albumin 
Human 
urine 
n/a 4 min MCE-UV 0.4 g L-1 Rapid protein urine 
analysis 
[142] 
Ocular 
dysfunction 
Peptide Pituitary 
adenylate 
Chicken 
endolym
Direct sampling 
using filter paper 
45 s MGE-LIF n/a Effect of pituitary 
adenylate cyclase 
[144] 
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cyclase 
activating 
polypeptide 
ph and 
rat tear 
strips activating polypeptide 
on protein 
composition in tears 
and endolymph 
Ocular 
dysfunction 
Small 
molecules 
K+, Na+, and 
Li+ 
Human 
tear 
Dilution 2 min MCE-EC 4.9, 6.8, and 9.0 
µM 
Disposable paper-
based device  
[145] 
Thyroid gland 
dysfunction 
Small 
molecule 
Thyroxine Human 
serum 
Protein 
precipitation, 
centrifugation 
1 min MCE-CL 2.2 nM Sensitive 
chemiluminescence 
immunoassay 
[146] 
(viii) Diabetes and pancreatic dysfunction  
Diabetes 
mellitus Protein 
Hemoglobin 
A1c 
Human 
blood Hemolysis 3 min MCE-EC 0.025 µg mL
−1
 
On-chip 
immunoassay using 
magnetic 
nanoparticles 
[149] 
Diabetes 
mellitus, diabetic 
nephropathy 
Protein 
Transferrin, β2-
microglobulin, 
human serum 
albumin and 
immunoglobuli
n G 
Human 
urine 
Centrifugation, 
filtration 5 min ITP-MCE-UV 0.05-0.6 mg L
-1
 
Integrated platform 
for sample 
preparation, 
enrichment and 
detection of 4 urinary 
proteins 
[150] 
Diabetes 
mellitus, diabetic 
nephropathy 
Protein Human 
albumin 
Human 
urine 
Protein 
denaturation <1 min MGE-LIF 7.5 mg L
-1
 
Alternative chip 
assay to standard 
enzymatic assay 
[151] 
Diabetes 
mellitus Protein 
Insulin-like 
growth factor-I 
Human 
serum 
Centrifugation, 
precipitation, 
reconstitution 
1 min FASI-MCE-LIF 0.68 ng mL-1 Sensitive competitive immunoassay [152] 
Pancreatic 
dysfunction Enzyme 
α-amylase 
isoenzyme 
Human 
plasma 
Density gradient 
centrifugation <2 min MGE-LIF 4.38 U L
-1
 
Alternative chip 
assay to standard 
enzymatic assay 
[153] 
(ix) Reproductive disorders 
Androgen 
disorders 
Small 
molecule Testosterone 
Human 
serum 
Anticoagulation, 
denaturation 30 s MCE-CL 1.0 nM  
Competitive 
immunoassay [154] 
Progesterone-
related disorders 
Small 
molecule Progesterone 
Human 
serum 
Protein 
precipitation, 
centrifugation, 
evaporation, 
reconstitution 
1 min MCE-CL 3.8 nM Competitive immunoassay [155] 
Preterm birth Peptides/Prot
eins 
Preterm birth 
biomarker 
peptides, 
Standar
ds None <50 s MCE-LIF n/a 
On-chip solid-phase 
extraction [156] 
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lactoferrin, 
ferritin 
Preterm birth Peptide 
Preterm birth 
biomarker 
peptide 1 
Human 
serum 
Dilution 10 s MCE-LIF 50 nM On-chip solid-phase 
extraction [157] 
CL, chemiluminescence; DEP, dielectrophoresis; EC, electrochemical; FASI, field-amplified sample stacking; IEF, isoelectric focusing; ITP, isotachophoresis; LIF, laser-
induced fluorescence, MCE, microchip zone electrophoresis; MGE, microchip gel electrophoresis; MS, mass spectrometry; n/a, not applicable; PCR, polymerase chain 
reaction. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
74 
 
Abbreviations 
APTS 8-aminopyrene-1,3,6-trisulfonic acid 
AUC Area-under-the-curve 
BGS Background solution 
bp Base pairs 
CE Capillary electrophoresis  
DEP Dielectrophoresis 
EGFR Epidermal growth factor receptor 
ELISA Enzyme-linked immunosorbent assay 
EOF Electroosmotic flow 
FITC Fluorescein isothiocyanate  
HA Heteroduplex analysis  
HDL High-density lipoprotein 
HPV Human papillomavirus  
HRP Horseradish peroxidase 
IGF-I Insulin-like growth factor-I  
JAK2 Janus kinase 2 
LDL Low-density lipoproteins  
LED Light-emitting diode 
LIF Laser-induced fluorescence  
lLDL Large, buoyant low-density lipoprotein  
IU International unit 
MCE Microchip electrophoresis 
MGE Microchip gel electrophoresis 
PACAP Pituitary adenylate cyclase activating polypeptide 
PCR Polymerase chain reaction 
PIVKA-II Prothrombin induced by vitamin K absence-II  
PMMA Poly(methyl methacrylate) 
PNA-PCR Peptide nucleic acid-mediated enriched polymerase chain reaction 
ROC Receiver operating characteristics 
sdLDL Small, dense low-density lipoprotein  
SDS Sodium dodecyl sulfate  
SSCP Single strand conformational polymorphism  
vLDL Very low-density lipoproteins  
VNTR Variable number of tandem repeats 
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Figure captions 
Figure 1. Schematic of a typical microchip electrophoresis system. 
 
Figure 2 Methodological approach for KRAS mutation detection using restriction fragment 
length polymorphism followed by microchip electrophoresis [77]. 
 
Figure 3. Electropherogram showing the serum N-glycans profile from a patient with 
colorectal cancer. Reprinted with permission from [79]. Copyright (2016) American 
Chemical Society. 
 
Figure 4 Schematic of immunoassay for carcinoembryonic antigen and α‐fetoprotein.  The 
offline HRP-antibody-labelled biomarkers were injected from sample reservoir 2 into the 
separation channel where the labelled biomarkers were separated.  A continuous supply of 
substrate during separation was provided from reservoir 5.  Upon reaction of HRP with the 
substrate, a product was formed that was amperometrically detected at 4. 
 
Figure 5 (i) Schematic of the affinity disk chip for the determination of bioactive cytokines.  
The bioactive cytokines (open circle) are captured using specific protein receptors 
immobilised on a glass substrate.  The sample matrix (squares) and the non-bioactive 
cytokines (black circle) are washed away.  The immobilised cytokines are labelled with a 
fluorescence tags and subsequently eluted and electropheretically separated.  In (ii), the 
electropherograms obtained from the analysis of skin biopsy samples of (A) normal subject 
and (B) patient with mild inflammatory lesions and (C) patient with severe recurrent 
inflammatory lesions are shown.  Figure reprinted from [97] with permission. 
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Figure 6.  (A) Photograph of “sample-in-answer-out” microfluidic chip for genotyping of 
warfarin hypersensitivity. (B) shows the electropherograms from dried blood stain and oral 
swab obtained by a “sample-in-answer-out” microfluidic genotyping platform. Reprinted 
with permission from [101]. 
 
Figure 7.  (A) Microfluidic device for isoelectric focusing of β-amyloid peptides. (B) Mass 
spectrum of 5 nL of (i) immunoprecipitated cerebrospinal fluid and (ii) immunoprecipitated 
and isoelectrically-focused cerebrospinal fluid.  Reprinted with permission from reference 
[111]. Copyright (2016) American Chemical Society. 
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Highlights  
 
• Microchip electrophoresis (MCE) performed immunoassays, genotyping, and small 
molecule determination that were relevant in clinical analysis. 
 
• MCE enabled fast separation of biomarkers which was a crucial step for disease 
identification. 
 
• There were only a few reports that fulfilled the promise of point-of-care diagnostics. 
 
• The MCE strategies are discussed based on the targeted diseases. 
 
• Recent advancements and challenges of MCE are highlighted.  
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